EP4208080A1 - Compositions et méthodes de prise en charge thérapeutique de patients souffrant d'insuffisance cardiaque - Google Patents

Compositions et méthodes de prise en charge thérapeutique de patients souffrant d'insuffisance cardiaque

Info

Publication number
EP4208080A1
EP4208080A1 EP21865231.1A EP21865231A EP4208080A1 EP 4208080 A1 EP4208080 A1 EP 4208080A1 EP 21865231 A EP21865231 A EP 21865231A EP 4208080 A1 EP4208080 A1 EP 4208080A1
Authority
EP
European Patent Office
Prior art keywords
patient
data
therapeutic
updated
therapeutic regimen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP21865231.1A
Other languages
German (de)
English (en)
Inventor
Raj KHANDWALLA
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cedars Sinai Medical Center
Original Assignee
Cedars Sinai Medical Center
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cedars Sinai Medical Center filed Critical Cedars Sinai Medical Center
Publication of EP4208080A1 publication Critical patent/EP4208080A1/fr
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/48—Other medical applications
    • A61B5/4836—Diagnosis combined with treatment in closed-loop systems or methods
    • A61B5/4839—Diagnosis combined with treatment in closed-loop systems or methods combined with drug delivery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/02—Detecting, measuring or recording pulse, heart rate, blood pressure or blood flow; Combined pulse/heart-rate/blood pressure determination; Evaluating a cardiovascular condition not otherwise provided for, e.g. using combinations of techniques provided for in this group with electrocardiography or electroauscultation; Heart catheters for measuring blood pressure
    • A61B5/021—Measuring pressure in heart or blood vessels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/02—Detecting, measuring or recording pulse, heart rate, blood pressure or blood flow; Combined pulse/heart-rate/blood pressure determination; Evaluating a cardiovascular condition not otherwise provided for, e.g. using combinations of techniques provided for in this group with electrocardiography or electroauscultation; Heart catheters for measuring blood pressure
    • A61B5/024—Detecting, measuring or recording pulse rate or heart rate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/72—Signal processing specially adapted for physiological signals or for diagnostic purposes
    • A61B5/7271—Specific aspects of physiological measurement analysis
    • A61B5/7275—Determining trends in physiological measurement data; Predicting development of a medical condition based on physiological measurements, e.g. determining a risk factor

Definitions

  • the present description relates to compositions, systems, and methods for management of heart failure therapeutics for heart failure patients.
  • clinical inertia which occurs when clinicians fail to initiate or intensify evidence-based therapy or achieve prescribed targets in their patients (such as, with blood pressure or blood sugar), reduces potential improvement in clinical outcomes for HF.
  • a method comprises: acquiring physiological sensor data of a patient from one or more physiological sensors; receiving a patient profile referenced to the patient, the patient profile comprising a therapeutic dosage regimen comprising at least one therapeutic agent and an associated dosage; processing the physiological sensor data using a model to modify the therapeutic dosage regimen and output an updated therapeutic dosage regime; and administering to the patient the updated therapeutic dosage regime.
  • target dosage for a given HF therapeutic agent is achieved with improved efficiency, which improves clinical outcomes for HF patients and reduces hospitalization and mortality risk.
  • a clinician may prescribe the use of a digital therapeutic decision engine for evaluation and/or management of a therapeutic regimen for a heart failure patient.
  • the decision engine may receive patient data input from an electronic health record (EHR) of the patient and from one or more remote monitoring devices (e.g., wearable devices and/or non- wearable devices). Using the patient data and the remote monitoring data, the decision engine may determine whether a patient is stable enough for a change in his or her medications.
  • EHR electronic health record
  • the decision engine may determine if clinician input is required, and if not, the decision engine may automatically provide an update to initiate at least one medication at an associated dosage or change (e.g., increase or decrease) dosage of or discontinue at least one other medication and/or check labs.
  • an associated dosage or change e.g., increase or decrease
  • the patient may receive one or more of an information that educates the patient on the rationale for the decision and a notification requesting for the patient’s acknowledgement.
  • data from the wearable devices and/or patient response input via a patient questionnaires embedded in a patient-side app may be used to monitor the patient for any medication side effects and/or intolerances over a patient response monitoring period.
  • a safety decision component of the decision engine may be executed, where the safety decision component provides evaluates the therapeutic regimen based on thresholds for kidney function, hyperkalemia, hypotension, and/or bradycardia, and provides updates to the therapeutic regimen to discontinue or decrease the dosage of a medication (e.g., a medication that was initiated).
  • recommendations may be provided which are then updated upon approval by a clinician.
  • the methods and systems described herein incorporate data derived from remote patient monitoring devices to determine an effective therapeutic treatment regimen or modify an existing regimen or maintain the existing regimen, or initiate one or more laboratory test procedures. Further, by monitoring the patient before as well as after updating a therapeutic regime, and adjusting medications according to patient response, customized and personalized heart failure therapy is efficiently executed. As a result, patient outcome for HF patients is improved, which reduces mortality risk and hospitalization.
  • the decision engine may process heart rate data collected by wearable heart rate monitors to output a new or modified therapeutic treatment regimen.
  • This may include monitoring of an average heart rate over periods of time (e.g. 1, 2, 3, 4, 5, or 6 hours, days, weeks) that would not be possible at a clinical visit.
  • utilization of longitudinal heart rate, electrocardiogram, and blood pressure data will allow delivery of therapeutic treatment regimens that may reduce mortality rates among patient populations. Therefore, disclosed are systems and methods for determining and implementing therapeutic dosage regimens based on feedback from wearable heart rate monitoring devices and blood pressure cuff measurements, among other input data.
  • FIG. 1 shows a schematic diagram of an example of a system for managing a therapeutic regimen of a patient diagnosed with heart failure, according to an embodiment of the disclosure
  • FIG. 2 shows a high-level flow chart of an example method for managing a therapeutic regimen of a patient based on input from one or more physiological sensors and patient data from a patient health record, according to an embodiment of the disclosure
  • FIG. 3 shows a high-level flow chart of an example method for managing a therapeutic regimen of a patient based patient stability, according to an embodiment of the disclosure
  • FIG. 4A shows a high-level flow chart of an example method for managing a therapeutic regimen of a patient based patient stability, according to another embodiment of the disclosure
  • FIG. 4B is a continuation of FIG. 4A;
  • FIG. 5 shows a high-level flow chart of an example method for updating a therapeutic regimen based on patient response, according to an embodiment of the disclosure
  • FIG. 6A shows a high-level flow chart of an example initiation and dosing engine for managing a therapeutic regimen of a patient when the patient is stable, according to an embodiment of the disclosure
  • FIG. 6B is a continuation of FIG. 6A;
  • FIG. 6C is a continuation of FIG. 6B;
  • FIG. 6D is a continuation of FIG. 6C
  • FIG. 7 shows a high-level flow chart of an example safety decision engine for managing a therapeutic regimen of a patient when the patient’s stability is less than a stability threshold, and/or when monitoring a patient response to an updated therapeutic regimen;
  • FIGS. 8A and 8B show example clinician interfaces including example patient data acquired from a health record of the patient, example recommendations/updates, and example alerts; according to various embodiments of the disclosure;
  • FIGS. 9A and 9B are tables of example therapeutics and different levels given for heart failure patients.
  • FIGS. 10A and 10B show example inputs, example indication of decision states, and example outputs generated for a patient during respective updates of the therapeutic regimen of the patient;
  • FIGS. 11A - 11C show example inputs, example indication of decision states, and example outputs generated for another patient during respective updates of the therapeutic regimen of the patient.
  • the present description relates to systems and methods for evaluating and/or managing a therapeutic regimen for a patient diagnosed with heart failure and undergoing treatment with one or more therapeutic agents for heart failure (HF).
  • systems and methods are provided for periodically evaluating and updating a therapeutic regimen of the patient diagnosed with heart failure using remote patient monitoring data from one or more remote patient monitoring devices and using patient health data from an electronic health record of the patient.
  • the therapeutic regimen is periodically evaluated and updated according to guideline-directed medical therapy using a decision-tree model and an evidence-based approach as discussed herein.
  • An example system for evaluating and/or managing a therapeutic regimen for a HF patient is shown at FIG. 1.
  • GDMT guideline-directed medical therapy
  • ACEi angiotensin-converting enzyme inhibitor
  • ARB angiotensin II receptor blocker
  • ARNI angiotensin receptor neprilysin inhibitor
  • BB beta-blocker
  • MRA mineralocorticoid receptor antagonist
  • GDMT cardiac glycoside
  • Clinical inertia poses one of the greatest obstacles in improving clinical outcomes in HF patients.
  • the methods and systems provided herein improve utilization of GDMT to achieve target doses of HF medications in a seamless and efficient manner while enabling monitoring of the patients to any medication update or change. Further, the methods and systems provide an evidenced-based approach utilizing physiological data output from one or more remote monitoring devices as well as patient health data from electronic health records to manage HF therapy.
  • a decision-tree based model is implemented by a therapeutic regimen evaluation processing system for evaluation and management of therapeutic regimen for patients diagnosed with heart failure and undergoing treatment with one or more therapeutic agents for HF.
  • An example method for managing a therapeutic regimen is shown at FIG. 2.
  • remote patient monitoring data from the one or more remote monitoring devices are used to evaluate a patient’s stability, and therapeutic regimen updates may be based on the patient’s stability.
  • a mode of operation of the decision engine may be based on the patient’s clinical stability.
  • An example method for determining the mode of operation of the decision engine is discussed at FIG. 3.
  • FIGS. 4A, 4B, and 5 describe an example decision-tree based approach that may be implemented in an initiation and dosing engine for up-titration, initiation, decreasing dosage or discontinuing a therapeutic agent. Further, one or more alerts to re-check laboratory tests may be provided. Further, FIG.
  • FIGS. 7 shows an example method that may be implemented in a safety decision engine to determine if one or more therapeutic agents that are currently prescribed to the patient is to be decreased in dosage or discontinues.
  • the safety decision engine may check for thresholds related to symptoms of drug side effects, acute kidney injury, hyperkalemia, hypotension, and bradycardia using remote patient monitoring (RPM) data. If the RPM detects that the patient has met any critical safety thresholds, then the safety decision engine may update the therapeutic regimen to decrease or discontinue the dosage of one or more medications. In some examples, the safety decision engine may recommend that the patient either discontinue or decrease the dosage of a medication, and the therapeutic regimen may be updated accordingly.
  • FIGS. 8A and 8B show example clinician-side interface of the decision engine.
  • FIGS. 9A and 9B are tables showing example HF medications and associated dosage.
  • FIGS. 10A, 10B, 11 A, 11B, and 11C show example input, decision states, and output recommendations for various therapeutic regimen updates.
  • the technical advantage of the methods and systems described herein includes improved patient therapeutic regimen monitoring and patient response monitoring outside clinical setting.
  • Another technical advantage of the methods and systems described herein is safe and efficient initiation and up-titration of GDMT -based therapeutic agents, which allows the therapeutic regimen to achieve target doses efficiently and quickly. As a result, GDMT utilization is increased, which improves patient outcomes and reduces mortality risk. Further, patient response monitoring after an update to the therapeutic regimen allows effective monitoring of side-effects and enables quick response to adjust medication.
  • the methods and systems described herein reduce clinician inertia.
  • Yet another technical advantage is effective customization of HF therapy with quick and efficient pathway to achieve and manage target levels of HF medications based on current physiological conditions of the patient, including past medical history, and previous GDMT intolerances or allergies.
  • the methods and systems described herein enables clinicians to personalize and optimize guideline directed medical therapy (GDMT) in patients with chronic heart failure (HF) and reduced ejection fraction (HFrEF). As a result, patient outcome is improved, and mortality risk and hospitalization in HF patients is reduced. Thus, the methods and systems described herein provides improvements in heart failure therapy.
  • EHR electronic health record
  • HFrEF reduced ejection fraction
  • FIG. 1 shows a block diagram of an example digital therapeutics system 100 that may be implemented for determining and/or updating a treatment regimen for patients diagnosed with a cardiovascular disease condition, such as heart failure.
  • the treatment regimen may include one or more therapeutic agents and corresponding dosage for the one or more therapeutic agents for cardiovascular disease condition.
  • HF heart failure
  • FIG. 1 shows a block diagram of an example digital therapeutics system 100 that may be implemented for determining and/or updating a treatment regimen for patients diagnosed with a cardiovascular disease condition, such as heart failure.
  • the treatment regimen may include one or more therapeutic agents and corresponding dosage for the one or more therapeutic agents for cardiovascular disease condition.
  • HF heart failure
  • the digital therapeutics system 100 includes one or more physiological sensors 106 for acquiring physiological sensor data from a patient. Indications of physiological parameters from the one or more physiological sensors are input into decision engine 152 to provide more accurate and reliable patient health evaluation which is used to evaluate and/or manage a therapeutic regimen for a heart failure patient, as further discussed below.
  • the one or more physiological sensors 106 may be configured as remote monitoring sensors for monitoring one or more physiological parameters of the patient.
  • the remote monitoring sensors may include one or more wearable sensors and/or devices, one or more non-wearable sensors and/or devices, or any combination thereof. Further, the one or more wearable sensors may be positioned directly or indirectly on human body.
  • the one or more wearable sensors may be configured as body-worn devices such as wrist-worn devices (e.g., smart watch, wrist band, etc.), neck-worn devices (e.g., necklace, etc.), ear buds, rings, straps, etc., body adhering devices (e.g., wearable patch, device with multiple adhering modules), embedded devices in clothing (e.g., body suit, vest, pant), glasses, keychains, shoes, etc.
  • Non-wearable sensors and/or devices may include but not limited to smart phones (including apps), hand-held devices, table-top blood pressure monitors, glucose meters, bed-side sleep monitors, etc.
  • the one or more physiological sensors 106 may include one or more of one or more blood pressure sensors 108 for acquiring blood pressure data, one or more photoplethy smogram (PPG) sensors 110 for acquiring PPG data, one or more electrocardiogram (ECG) sensors 112 for acquiring ECG data, one or more stability sensors 114 for acquiring patient mobility and/or stability data, and one or more audio sensors 116 for acquiring auscultation data.
  • the one or more physiological sensors 106 may additionally include other sensors 117, such as electromyogram (EMG) sensors, EEG sensors, temperature sensors, biochemical sensors, biomechanical sensors, and implantable sensors.
  • EMG electromyogram
  • Blood Pressure Sensors [0047] Hypertension or high blood pressure is a medical condition that increases the risks of cardiovascular diseases, and other diseases. Patients with hypertension may require periodic or continuous monitoring of blood pressure to prevent progression to heart failure. Further, blood pressure monitoring is also important in patients with established heart failure. Accordingly, in order to evaluate a therapeutic regimen for a HF patient, update the therapeutic regimen, and/or provide one or more alerts that facilitate continuous evaluation and/or update of the therapeutic regimen, blood pressure measurements are used. Accordingly, the one or more blood pressure sensors 108 may acquire blood pressure data from the patient, which is used to obtain blood pressure measurements, including ambulatory blood pressure measurement and/or standard blood pressure measurements.
  • the one or more blood pressure measurements may include one or more of systolic blood pressure (SBP) and diastolic blood pressure (DBP).
  • the one or more blood pressure sensors 108 may be configured as wearables or home-based monitoring devices.
  • a patient may be trained and/or guided to perform home-based blood pressure measurement using a homebased blood pressure monitoring device.
  • the patient may be guided with regard to positioning of a blood pressure cuff of the home-monitoring device, and blood pressure data may be acquired via the home-monitoring device, which may automatically output one or more blood pressure measurements.
  • a blood pressure sensor when configured as a wearable device (e.g., a wrist watch), the blood pressure data may be automatically acquired and the blood pressure may be automatically calculated.
  • data from a combination of sensors e.g., ECG and PPG data
  • data from another type of sensor ECG data or PPG data alone
  • ECG data or PPG data alone may be used for measuring SBP and/or DBP.
  • ECG monitoring may be used to estimate and/or measure various cardiac parameters, including but not limited to heart rate (HR), hear rate variability (HRV), heart rhythm abnormalities (QT interval changes, QRS irregularities, ST segment changes, etc.) atrial arrhythmias, and ventricular arrhythmias.
  • HR heart rate
  • HRV hear rate variability
  • HRV heart rhythm abnormalities
  • QRS irregularities QRS irregularities
  • ST segment changes etc.
  • the one or more ECG sensors may be configured to acquire single-lead, or multi-lead data (e.g., two-lead, three-lead, six-lead, ten-lead, 12-lead etc.)
  • the one or more ECG sensors 112 may be configured as a wearable or non- wearable ECG monitoring device.
  • a wearable ECG monitoring device including one or more ECG sensors may be worn by the patient or attached to a patient, and ECG data of the patient may be acquired via the wearable device in a continuous manner or at pre-determined intervals or in response to user initiation.
  • a hand-held ECG monitoring device may be used to acquire ECG data.
  • the ECG monitoring device may be placed at specific anatomical positions on the body in order to acquire multi-lead data.
  • a PPG sensor may include at least one light source, (e.g., an LED) and at least one photodetector (e.g., a photodiode). Using the photodetector, PPG signals indicative of blood flow through the vessels may be generated, which may be used for measuring and/or estimating one or more physiological parameters of the patient (e.g., heart rate, respiration rate, heart rate variability, pulsatile blood oxygenation estimate (SpO2), blood pressure, etc.).
  • PPG sensors may be used in addition to or alternative to ECG sensors.
  • PPG sensors may be configured as wearables or non-wearable devices, and may be placed at anatomical positions such as the earlobe and fingertip where the desired PPG signals are collected with higher quality.
  • Evaluation of patient stability e.g., patient balance when in an upright stance, postural sway, etc
  • patient mobility e.g., changes in gait
  • the patient mobility and/or stability evaluation may be used to determine a mode of operation of a decision engine for HF therapeutic regimen management as discussed in detail further below.
  • the patient mobility and/or stability evaluation may be performed via data acquired from one or more stability and/or motion sensors 112.
  • a mode of operation of the decision engine that may result in an initiation of a therapeutic agent or up-titration of a therapeutic agent may be based on whether or not stability evaluation indicates that the patient meets the desired stability thresholds.
  • the decision engine may be operated in a mode that may evaluate if one or more therapeutic agents may be discontinued or decreased or if one or more lab tests are required. Details of the different modes of the decision engine are discussed further below.
  • the one or more stability and/or motion sensors 112 may include one or more accelerometers and/or one or more gyroscopes.
  • the inertial sensors embedded in smart devices can be used to measure patient stability and/or patient mobility.
  • data acquired from an accelerometer and/or a gyroscope included within a smartphone (e.g., iPhone), a smart watch (e.g., Apple watch) or a smart table (e.g. iPAD) may be used to evaluate stability of a patient.
  • data from the accelerometer and/or the gyroscope may be used to calculate an equilibrium score, which may indicate a degree sway of a patient.
  • a wearable device may include one or more accelerometers (e.g., a biaxial accelerometer, a triaxial accelerometer, etc) and/or one or more gyroscopes (e.g., a biaxial gyroscope, a triaxial gyroscope, etc.), which may be used to acquire stability data and evaluate a stability of a patient.
  • the one or more stability and/or motion sensors 112 may be configured as an inertial measurement units (IMUs) comprising accelerometers, gyroscopes, and magnetometers.
  • the IMUs may be placed on specified positions on the leg (e.g. shank, foot, etc), and data from the IMUs may be used to evaluate gait irregularities and/or stability.
  • one or more audio sensors 116 may be used to evaluate heart sounds of the patient.
  • the one or more audio sensors 116 may be used to perform auscultation, and audio data from the one or more audio sensors 116 may be used in the determination of whether to maintain or update a therapeutic regimen or generate one or more alerts (e.g., alerts to perform a specific lab test, perform basic metabolic panel, etc.).
  • Biochemical sensors include electrochemical transducers configured to measure body fluid electrolyte parameters, such as analyte concentrations.
  • sensors configured to analyze sweat, saliva, and/or hydration may be used.
  • Biomechanical sensors such as ballistocardiogram-based sensor, seismocardiogram-based sensors, and dielectric sensors, may be used to continuously measure variables such as cardiac output, lung fluid volume and weight.
  • an accelerometer placed on a patient’s chest may be used to generate a seismocardiogram (SCG), which is a measure of thorax accelerations produced by the beating heart.
  • SCG seismocardiogram
  • SCG data may be additionally used in evaluating and/or management of a therapeutic regimen for HF.
  • data from one or more additional sensors such as EMG, EEG, temperature sensors, and/or implantable cardiac monitor (e.g., for AF detection, monitoring pulmonary artery pressure, etc.) may be used in the evaluation and/or management of the therapeutic regimen for HF.
  • a multi-sensor module that includes a plurality of the physiological sensors may be used to acquire multi-sensor data from the various sensors simultaneously, and process the multi-sensor data to estimate and/or measure a plurality of physiological parameters (heart rate, systolic blood pressure, diastolic blood pressure, weight, temperature, stability, oxygen saturation, respiration rate, stability, etc.), which may be used as input parameters for a decision engine configured to evaluate and/or manage a therapeutic regimen for HF.
  • physiological parameters herein, systolic blood pressure, diastolic blood pressure, weight, temperature, stability, oxygen saturation, respiration rate, stability, etc.
  • one or more monitoring devices may be used to acquire physiological sensor data from a patient, where each of the one or more monitoring devices includes one or more physiological sensors 106.
  • a patient may be a blood pressure monitoring device, a second monitoring device that may be an ECG and/or a heart sound monitoring device; and a third monitoring device that may be a stability monitoring device.
  • Physiological sensor data from each of the devices may be acquired sequentially or simultaneously within a desired time-window for evaluation and/or management of a therapeutic regimen for HF.
  • data from some of the sensors may be acquired simultaneously.
  • data from sensors that generate waveform data may be acquired simultaneously and in a time-synchronized manner (e.g., ECG and audio sensors; ECG and PPG; ECG, audio, and PPG; ECG, PPG, and ECG; etc).
  • data from other physiological sensors such as blood pressure sensor, may be acquired independently but within the desired time-window when sensor data for evaluation and management of a therapeutic regimen is acquired.
  • each of the one or more physiological sensors or each of the one or more monitoring devices may include an integrated processor that is integrated with a respective sensor (or device).
  • the respective integrated processors may process the corresponding data acquired via the respective sensors and generate a corresponding output, which is then transmitted to the decision engine for determining whether any modification to a current treatment regimen may be performed.
  • a computing device 120 may be communicatively coupled to the one or more physiological sensors (and/or monitoring devices) 106 and a therapeutic regimen evaluation server 150. Further, the computing device 120 may receive data from and send data to the one or more physiological sensors 106 a connection 118, which may be wired, wireless (e.g., WiFi, ZigBee, Bluetooth, 5G, etc.), or a combination thereof. Further, the computing device 120 may send data to and receive data to the server 150 via communication network 140, which may be wired, wireless, or a combination thereof.
  • the computing device 120 may be any suitable computing device, including a computer, laptop, mobile phone, tablet, etc.
  • the computing device 120 includes one or more processors 126, one or more memories 132, and a user interface 134 for receiving user input and/or displaying information to a user.
  • the computing device 120 may be configured as a mobile device and may include a patient-side application 136, which represents machine executable instructions in the form of software, firmware, or a combination thereof.
  • the components identified in the application 136 may be part of an operating system of the mobile device or may be an application developed to run using the operating system.
  • application 136 may be a mobile application.
  • the application 136 may also include web applications, which may mirror the mobile application, e.g., providing the same or similar content as the mobile application.
  • the application 136 may include a patient interface and may assist a patient in acquiring physiological sensor data for evaluation and/or management of therapeutic regimen for HF, input estimates and/or measurements of one or more physiological parameters based on remote monitoring by the patient, and receive notifications and/or alerts from the decision engine.
  • a patient may receive notifications to initiate physiological sensor data acquisition for therapeutic regimen evaluation, input estimated and/or measured physiological parameter values for further processing via the decision engine 152, receive notification based on output from the decision engine regarding any updates to the therapeutic regimen, provide confirmation and/or acknowledgement of updates, input reactions to an updated regimen, and receive notification regarding pending and/or additional laboratory tests that may be required for evaluation and/or management of the therapeutic regimen, among other features.
  • the patient may receive therapeutic regimen updates, recommendation, notifications, alerts, and other HF therapeutic regimen related information from the server through the application 136.
  • the application 136 may (1) display vital signs, (2) display activity, (3) display a medication list, (4) display medication reminders, (5) therapeutic and dosage recommendations, (6) patient content including instructional videos, (7) enable input of side effects from patient, (8) enable therapeutic regimen notification/update/change confirmation, and (9) other HF therapeutic regimen related information.
  • the application 136 may be used to initiate physiological sensor data acquisition from the one or more physiological sensors 106 (and/or one or more monitoring devices) for evaluation and/or management of therapeutic regimen for HF. Further, in one example, the application 136 may be configured to receive physiological sensor data from the one or more physiological sensors 106 (and/or one or more monitoring devices), pre-process the physiological sensor data (e.g., apply filtering, normalizing to improve signal quality and reduce noise), and transmit the pre-processed sensor data to a therapeutic regimen server 150 (indicated by 144) for estimating and/or measuring one or more physiological parameters from the physiological sensor data. The estimated and/or measured physiological parameters (heart rate, stability, systolic BP, diastolic BP, etc) may then be used as input into the decision engine 152 for evaluation and/or management of the therapeutic regimen for HF.
  • respective physiological sensor data from the one or more physiological sensors 106 may be processed via respective mobile or web applications in the computing device 102 (and via respective application programming interfaces (APIs)), and the estimated and/or measured physiological parameter from the respective physiological sensor may be used as input to the decision engine 152.
  • the respective physiological parameter(s) estimated and/or measured via each physiological sensor may be automatically transmitted to the decision engine 152.
  • a user may input one or more estimated and/or measured physiological parameters via the application 136.
  • the user may input some of the physiological parameters, while the remaining estimated and/or measured physiological parameters may be automatically input into the decision engine.
  • the computing device 102 may include one or more sensors (e.g., gyroscope 128, accelerometer 124, etc.) and raw or pre-processed data from the one or more sensors may be accessed via respective framework or APIs.
  • gyroscope and/or accelerometer data from the computing device 120 may be used to determine one or more stability parameters (e.g., degree of sway) of the patient, which may be input automatically (e.g., via application 136 to server 150 or from server 150 depending on how the raw or pre-processed data is processed to obtain the physiological parameter) to the decision engine.
  • stability parameters e.g., degree of sway
  • one or more physiological sensor datasets from the one or more physiological sensors 106 may be transmitted to the therapeutic regimen evaluation server 150 via the computing device 120 and/or a communication network 140, and a preprocessing step (e.g., to remove noise) may be performed at server 150 or at the computing device 102.
  • the server 150 may be configured to receive one or more physiological sensor datasets (raw or pre-processed) from the one or more physiological sensors 106 via the computing device 120 and/or the network 140.
  • the network 140 may be wired, wireless, or various combinations of wired and wireless.
  • the one or more physiological sensors 106 may be pre-associated with the therapeutic regimen evaluation server 150.
  • the one or more physiological sensors 106 may be a network of inter-connected devices pre-associated with the therapeutic regimen evaluation server 150.
  • an intermediate gateway may be used to link the physiological sensors 106 with the server 150, and the server 150 may receive estimated and/or measured physiological parameter values via the intermediate gateway.
  • the server 150 may interact with one or more respective platforms of the respective physiological sensors, and selected information, such as one or more physiological parameters estimated and/or measured using data acquired via the respective physiological sensor, may be received by the server 150 from the sensor platform.
  • a blood pressure monitoring platform may estimate and/or measure one or more of SBP and DBP of a patient based on data acquired via the blood pressure sensor 108, and the SBP and/or DBP value may be received by the server 150 from the blood pressure monitoring platform.
  • the therapeutic regimen server 150 includes one or more processors 149 and one or more non-transitory memories 151.
  • the one or more processors 149 may include machine readable instructions stored in non-transitory memories 151.
  • the one or more memories 151 may store a decision engine 152 for performing evaluation and/or management of a therapeutic regimen for a HF patient.
  • the decision engine 152 includes a stability processing logic 153 for evaluating a stability of a patient.
  • stability of the patient may be evaluated periodically at desired intervals in order to determine whether to initiate an evaluation of a therapeutic regimen.
  • stability of the patient may be evaluated to determine a mode of operation of the decision engine, as discussed further below.
  • the decision engine 152 further includes a safety decision engine 154 for determining whether one or more therapeutic agents (that is, medications) in a therapeutic regimen may be decreased or discontinued or whether another laboratory test may be needed for the patient.
  • the decision engine further includes an initiation and dosage engine (IDE) 155 for determining updates to the therapeutic regimen, including initiation of new medications and an up-titration of one or more therapeutic agents. Accordingly, the updates to the therapeutic regimen based on IDE may also include maintaining current regimen, down-titration, or discontinuation of one or more therapeutic agents, and one or more alerts to perform one or more laboratory tests.
  • IDE initiation and dosage engine
  • the decision engine 152 may be operated in a first mode, wherein the IDE 155 is executed, or in a second mode, wherein only the safety decision engine 154 is executed. Details of the decision engine, including the different modes of operation of the decision engine will be discussed below.
  • the decision engine 152 further includes an electronic health record (EHR) processing logic 156 for receiving patient information from an EHR system 162.
  • the EHR system 162 includes an EHR server 166 and an EHR database storing patient health information.
  • the EHR system 162 may further include an EHR interface server (not shown) for interfacing with the therapeutic regimen evaluation server 150.
  • the decision engine 152 may be integrated within the EHR system 162.
  • the decision engine 152 receives patient data from the EHR, via network 141, for example.
  • a clinician computing device 170 may be communicatively coupled to the therapeutic regimen evaluation server 150 via network 141.
  • the network 141 may be a wireless network, a wired network, or any combination of wireless and wired networks.
  • the therapeutic regimen evaluation server 150 may include a cardiac health database 160 for storing therapeutic regimen information for each patient.
  • the therapeutic regimen information may include a current therapeutic regimen, updates made to the current therapeutic regimen by the decision engine and/or the clinician, history of all therapeutic regimens prescribed to the patient, history of updates to each therapeutic regimen, information regarding accepted changes, information regarding prescription transmitted to pharmacy systems 190 etc.
  • the clinician computing device 170 includes at least one processor 176, at least one non-transitory memory 182, and a user interface 184, which may be a user input device.
  • the user interface 184 may be a user input device, and may comprise one or more of a touchscreen, a keyboard, a mouse, a trackpad, a motion sensing camera, and other device configured to enable a user to interact with and manipulate data within the processing system 102.
  • the user interface may include a display portion (not shown).
  • the display may be combined with processor 176, non-transitory memory 182, and/or user interface 184 in a shared enclosure, or may be peripheral display devices and may comprise a monitor, touchscreen, projector, or other display device known in the art, which may enable a user to view patient sensor data, patient EHR data, and/or interact with various data stored in non- transitory memory 182, and/ or database 160.
  • the clinician computing device 170 may be a workstation communicatively coupled to the EHR system 162, via network 141, for example.
  • the clinician computing device 170 further includes a clinician application 186. Similar to application 136 at the patient-side computing device 120, the clinician application 186 represents machine executable instructions in the form of software, firmware, or a combination thereof. Further, the components identified in the application 186 may be part of an operating system of the computing device 170 or may be an application developed to run using the operating system. Further, the application 186 may include a clinician interface that allows an authenticated clinician to prescribe, review, confirm, and/or make any changes to a therapeutic regimen.
  • the application 186 may allow an authenticated clinician to review a patient’s EHR, input data from the EHR into the decision engine, and/or input patient monitoring data (e.g., from a clinical visit) into the decision engine. Further still, the application 186 may enable the clinician to selectively initiate therapeutic regimen evaluation by the decision engine 152 at any time.
  • the clinician interface may (1) display vital signs of the patient, including physiological parameters estimated and/or measured using one or more physiological sensors (2) display relevant medical history, (3) display a medication list including dosage, (4) display generated orders, (5) therapeutic and dosage recommendations, (6) display alerts, (7) allow input of side effects from the clinician, and (8) display logic that caused the generated orders and/or alerts.
  • FIGS. 8A and 8B Non-limiting examples of a clinician interface are shown at FIGS. 8A and 8B.
  • an example system for implementing the disclosed technology may include a computing device with a display, a communications network, a patient, one or more remote monitoring sensors, and a server and associated database, where the server and the associated database are communicatively coupled to the computing device via the communications network.
  • the computing device may be any suitable computing device, including a computer, laptop, mobile phone, etc.
  • the network may be wired, wireless, or various combinations of wired and wireless.
  • the server and the associated database may be local, remote, and may be combinations of servers and databases, or could be local processors and memory.
  • the one or more remote monitoring sensors may be a smart phone, smart watch, smart ankle bracelet, smart glasses, smart ring, patch, band, or other device that suitably could be retained on the patient and output physiological parameter data from the patient.
  • the physiological parameter data may include, but not limited to, heart rate data, blood pressure data, body temperature data, oxygen saturation data, respiratory rate data, patient balance stability data, and patient mobility data.
  • the remote monitoring device may be a clinical grade ECG system when a patient is in a hospital.
  • the remote monitoring device may be a camera on a mobile device and may record the heart rate data by fluctuation in colors of the capillaries detected by the camera.
  • the decision engine may be executed during a remote clinical visit and/or prior to a remote visit with a clinician. In some other examples, the decision engine may be executed prior to a clinical visit.
  • FIG. 2 is a high-level flow chart illustrating an example method 200 for evaluation and/or management of a therapeutic regimen for a HF patient, according to an embodiment of the present disclosure.
  • method 200 and all methods described herein may be implemented based on instructions stored in non-transitory memory of a processing system, such as a therapeutic regimen evaluation server 150, an edge device connected to the processing system, a cloud in communication with the processing system, or any combination thereof.
  • a processing system such as a therapeutic regimen evaluation server 150, an edge device connected to the processing system, a cloud in communication with the processing system, or any combination thereof.
  • the method 200 will be described with respect to FIG. 1; however, it will be appreciated that the method 200 may be implemented using similar systems without departing from the scope of the disclosure.
  • the method 200 begins at 202.
  • the method 200 includes determining if entry conditions for performing a therapeutic regimen evaluation and/or management for a HF patient is met.
  • the entry conditions may be based on one or more of a desired schedule for the patient. For example, one or more physiological parameters (e.g., systolic blood pressure, average systolic blood pressure, heart rate, average heart rate, etc.) and/or patient data (from EHR) may be monitored according to the desired schedule for the patient to determine if entry conditions are met.
  • physiological parameters e.g., systolic blood pressure, average systolic blood pressure, heart rate, average heart rate, etc.
  • patient data from EHR
  • the patient may be monitored using remote monitoring data on a daily basis, and as such, the desired schedule may include a number of times a day, where the number of times may be 1, 2, 3, 4, 5, 6 or more times a day. In some examples, continuous monitoring of one or more physiological parameters may be performed. In some examples, the desired schedule may be every week, every 2 weeks, every 3 weeks, or every 4 weeks. In some examples, the entry conditions may be met when a new lab result is indicated in the patient’s EHR. As such, method 200 may be iterative and may take into account periodic changes to the heart failure therapeutics, dosages, and/or times of administration (or other factors). In one example, the desired schedule may be specified by a clinician.
  • the desired schedule may be automatically generated based on a cardiac health condition of the patient.
  • the desired schedule may be customized (either automatically or based on clinician recommendation) for each patient.
  • the entry conditions may be met if a new laboratory test result and/or a cardiac imaging result has been generated in the EHR.
  • the laboratory may include a basic metabolic test or a comprehensive metabolic panel, and/or a complete blood count.
  • the cardiac imaging result may include a new echocardiogram indicating an updated left ventricular ejection fraction (LVEF), or any cardiac imaging result (e.g., nuclear profusion studies, Cardiac Single Photon Emission Computed Tomography, Cardiac Magnetic Resonance Imaging, etc.).
  • LVEF left ventricular ejection fraction
  • entry conditions may be met if an ejection fraction is less than 40% and/or a systolic blood pressure is greater than 140. If the entry conditions are not met, the answer at 202 is NO, and the method 200 proceeds to 204.
  • the method 200 includes not initiating an initiation and dosing engine, such as the initiation and dosing engine 152 discussed at FIG. 1. Further details of the initiation and dosing engine will be described below at FIGS. 6A - 6D.
  • the method 200 includes receiving sensor data from the HF patient.
  • the sensor data may include one or more physiological parameter values estimated and/or measured from data acquired via one or more physiological sensors, such as the one or more physiological sensors 106, pre-associated with the initiation and decision engine.
  • the sensor data may include one or more datasets from the one or more physiological sensors.
  • the one or more datasets may include raw or pre-processed data acquired via the one or more physiological sensors, and accordingly, in one example, the initiation and dosing engine may estimate and/or determine one or more physiological parameters based on the one or more datasets.
  • the sensor data may include ECG data 212 (acquired via an ECG sensor), blood pressure data 214 (acquired via a BP sensor), stability data 216 (acquired via a gyroscope), and other sensor data 218, such as PPG, SCG, audio sensor data, etc.
  • the sensor data may include a heart rate and/or an average heart rate over a threshold duration (estimated and/or measured based on one or more sensor data, such as ECG data and PPG data).
  • the sensor data may further include an average SBP over the threshold duration, an average DBP over the threshold duration, and a minimum systolic BP estimated and/or measured over the threshold duration.
  • the sensor data may further include a degree of stability calculated based on gyroscope data.
  • the sensor data may include a combination of datasets. For example, raw or pre- processed to remove noise, etc may be received from some of the physiological sensors, while estimated and/or measured values may be received from the remaining physiological sensors.
  • the average SBP value, the average DBP value, and the minimum DBP value, determined at a remote blood pressure sensor may be received while ECG dataset and gyroscope dataset may be received from the ECG sensor and the gyroscope.
  • the processing system e.g., server 150
  • an indication may be transmitted to a patient computing device (e.g., computing device 120) or automatically generated via an application (e.g., app 136) running at the patient computing device.
  • the indication may include a notification and/or associated instructions for acquiring one or more sensor data from the one or more physiological sensors.
  • the patient may automatically initiate acquisition of data from the one or more physiological sensors via the application (that is, the patient interface of the decision engine).
  • a time window may be provided within which the patient may acquire all the necessary physiological sensor data.
  • the acquisition of sensor data may be automatically initiated (either via patient initiating automatic acquisition from all interconnected sensors through the application (e.g., via a single click) or automatically initiated without patient initiation) responsive to the entry conditions being met.
  • the method 200 may include receiving periodic sensor data readings, including a heart rate every 5 seconds, every 30 seconds, every minute, every five minutes, every hour, every day or other suitable times, including in-between the recited timing. Therefore, averages of sensor readings may be determined over longer time periods, without a patient consciously measuring the heart rate at their chosen times.
  • the method 200 includes receiving patient data referenced to a specific patient profile in a memory, database, or other suitable storage system (e.g., EHR).
  • the patient data may include therapeutics and dosages 222, height and weight 224, medical history 226, ejection fraction 228, side effects 230, and other data.
  • the therapeutics and dosages 222 may include a history of heart failure therapeutics administered to the patient, the dosages, and the accompanying sensor data 210 and side effects for particular therapeutics and dosages.
  • the medical history may contain various information about conditions of the patient and other relevant information to heart failure conditions.
  • Various side effects 230 may be entered by the patient through an interface (e.g., application 136 at FIG. 1) and/or may be monitored by the sensors and detected from the sensor data 210.
  • the initiation and dosage engine may detect cardiac events from the electrocardiogram data 212, heart rate changes that are outside acceptable thresholds, or blood pressure changes that are outside acceptable thresholds.
  • Other qualitative side effects may be entered by the patient including nausea, dizziness, tiredness and others.
  • the patient will be prompted at regular time intervals to check or enter any side effects they are experiencing (including from a standard list).
  • data from one or more remote monitoring devices may be input into the initiation and dosage engine.
  • data may be input into the initiation and dosage engine from an electronic health records system.
  • the sensor and the EHR data may be input into the initiation and decision engine to evaluate and/or output an updated therapeutic regimen.
  • the information from the electronic health records system may include the various patient data including (1) basic metabolic information such as potassium, creatinine, delta creatinine, estimated Glomerular Filtration Rate (eGFR), etc., (2) height and weight, (3) therapeutic history (past and present), (4) active and past conditions, (5) surgical history, (6) ejection fraction data, (7) drug allergies, and (8) other information.
  • basic metabolic information such as potassium, creatinine, delta creatinine, estimated Glomerular Filtration Rate (eGFR), etc.
  • eGFR estimated Glomerular Filtration Rate
  • the sensor data (from 210) and the patient data (from 220) may be input into the initiation and dosage engine and processed to output an updated treatment regimen 234 that may include at least one therapeutic or more and accompanying dosages 236.
  • the initiation and dosage engine (IDE) may include decision trees that utilize threshold values for various physiological parameters.
  • IDE may utilize, physiological sensor data, including average heart rate, average systolic blood pressure, minimum systolic blood pressure, respiratory rate, oxygen saturation, and temperature.
  • Respective threshold values or ranges for one or more of the above-mentioned physiological sensor data and patient data may be initialized at the time of prescription of the IDE or updated at any time during the course of the therapeutic regimen. For instance, the system may determine whether to titrate or change medication if average heart rate for an extended period of time (e.g. four hours) is over a certain level. Details of the initiation and dosage engine is discussed below at FIGS. 6A - 6D.
  • the method 200 includes treating the patient by administering the therapeutics and dosages to the patient required by the updated treatment regimen. In some examples, this may include prescribing the therapeutic to the patient and requiring the patient to take the drug at certain intervals with certain dosages (e.g. 12 mg every 12 hours).
  • FIG. 3 shows a high-level flowchart illustrating an example method 300 for operating a decision engine for evaluation and/or monitoring of a therapeutic regimen of a HF patient, according to an embodiment of the present disclosure.
  • the method 300 may determine a mode of operation of a decision engine, such as decision engine 152, based on input from one or more physiological sensors, such as one or more physiological sensors 106, and from the patient’s EHR, such as EHR system 162.
  • the method 300 begins at 302.
  • the method 300 includes receiving input from one or more physiological sensors and the patient’s EHR.
  • Input from the one or more physiological sensors may include one or more physiological parameters estimated and/or measured using data acquired via the one or more physiological sensors. Details of the input from the one or more physiological sensors and the EHR are discussed above with respect to step 210 and step 220 at FIG. 2, and will not be repeated for the sake of brevity.
  • the one or more physiological parameters may include, but not limited to, average heart rate, heart rate variability, average SBP, average DBP, minimum SBP, current weight, a degree of stability, clinical stability, respiratory rate, oxygen saturation, and temperature.
  • the patient data from the EHR may include, but not limited to, presence of implanted devices (e.g., ICD, pacemaker), current and past health conditions (e.g., diabetes, hypertension), medication intolerance, sex, weight, creatinine level (Cr), change from previous creatinine (dCr), potassium levels (K), eGFR value (eGFR), current therapeutic agents (that is, medications) and their corresponding dosage.
  • some of the physiological parameters such as systolic blood pressures and heart rate readings remotely monitored via respective physiological sensor and/or remote monitoring devices may be averaged through a specified monitoring period.
  • the monitoring period may be 5 seconds, 30 seconds, one minute, five minutes, 30 minutes, 1 - 24 hours, 1 - 6 days, 1 - 2 weeks, or other suitable times, including in-between the above-mentioned timings.
  • the method 300 includes determining if the patient is stable for up-titration or initiation of one or more medications.
  • stability may be determined based on remote monitoring data over a stability monitoring duration.
  • the clinical stability may be based on average heart rate (e.g., determined based on one or more of ECG data and PPG data), average systolic blood pressure (e.g., determined based on blood pressure data), average respiratory rate (e.g., determined based on PPG data), average oxygen saturation (e.g., determined based on PPG data), and average temperature (e.g., determined based on body temperature data).
  • a degree of stability may be determined with respect to one or more of a standing posture, walking steadiness, step length, walking speed, walking asymmetry, and indications of syncope.
  • the clinical stability may be determined based on a clinical stability score greater than a threshold score, the clinical stability score determined based on the average heart rate, average systolic blood pressure, average respiratory rate, average oxygen saturation, average temperature, and degree of stability, each compared to respective thresholds or respective threshold ranges.
  • the stability may be confirmed based on each of the clinical stability parameters (that is, the average heart rate, average systolic blood pressure, average respiratory rate, average oxygen saturation, average temperature, and degree of stability) remaining within respective thresholds or threshold ranges during the stability monitoring period.
  • two or more stability parameters may be used for stability monitoring. That is, two or more of the average heart rate, average systolic blood pressure, average respiratory rate, average oxygen saturation, average temperature, and degree of stability may be used for stability evaluation.
  • the average heart rate and average systolic blood pressure may be used for stability monitoring.
  • stability indication may be obtained from a wearable, such as a smart watch, configured to calculate one or more a standing posture, walking steadiness, step length, walking speed, walking asymmetry, and indications of syncope.
  • indications from patient may also be taken in to account in determining stability.
  • a patient may indicate, via a patient-side application (e.g., app 136), regarding one or more stability-related conditions, such as dizziness, lightheadedness, fainting etc.
  • the processor may assess patient stability taking into account patient provided stability input.
  • the method 300 includes running the initiation and dosing engine, which also includes the safety decision engine.
  • the initiation and dosing engine may automatically initiate, discontinue, and/or update (increase or decrease) a dosage of one or more therapeutic agents based on guideline directed medical therapy (GDMT) using a patient’s remote monitoring device data (that is, data from one or more physiological sensors) and the EHR data. Details of the initiation and dosage engine is described with respect to FIGS. 6A - 6D below.
  • GDMT guideline directed medical therapy
  • the method 300 Upon running the initiation and dosing engine, the method 300 proceeds to 330.
  • the method 300 includes generating an initiation and dosing engine output.
  • the output includes recommendations to maintain a current therapeutic regimen or update the current therapeutic regimen.
  • updating the current therapeutic regimen may include performing one or more of initiation of one or more new therapeutic agents (332), discontinuation of (338) or change in dosage of one or more previously administered therapeutic agents (that is, change in dosage of one or more therapeutic agents that are currently prescribed and taken by the patient) and re-check laboratory and/or imaging test (340) (e.g., basic metabolic profile, recheck LVEF, eGFR, etc.).
  • the change in dosage of the one or more previously prescribed therapeutic agents may include increasing (334) or decreasing (336) dosages associated with the therapeutic agents.
  • Each of the one or more new therapeutic agents and each of the one or more previously administered therapeutic agents may be selected from the group consisting of beta blockers, Angiotensin-converting enzyme (ACE) inhibitors, angiotensin receptor blockers (ARBs), Angiotensin receptor-neprilysin inhibitors (ARNis), Aldosterone receptor antagonists (MRAs), Sodium-glucose transport protein (SGLT2) inhibitors, and other therapeutic agents for treating heart failure.
  • ACE Angiotensin-converting enzyme
  • ARBs angiotensin receptor blockers
  • ARNis Angiotensin receptor-neprilysin inhibitors
  • MRAs Aldosterone receptor antagonists
  • SGLT2 Sodium-glucose transport protein
  • each therapeutic agent may be selected from the group consisting of Bisoprolol, Carvedilol, Metoprolol Succinate, Captopril, Enalapril, Fosinopril, Lisinopril, Perindopril, Quinapril, Ramipril, Trandalopril, Candesartan, Losartan, Valsartan, Olmesartan, Sacubitril / Valsartan, Spironolactone, Eplerenone, Dapagliflozin, Empagliflosin, Canagliflozin, Ertugliflosin, and other therapeutic agents for heart failure therapy.
  • the check lab output may be generated responsive to one or more of a potassium level greater than a potassium level threshold, a delta creatinine level greater than a delta creatinine level threshold, initiation of an MRA class of therapeutic agent, initiation of an Angiotensin-converting enzyme (ACE) inhibitor, initiation of an angiotensin receptor blocker (ARBs), and initiation of an Angiotensin receptor-neprilysin inhibitors (ARNis).
  • ACE Angiotensin-converting enzyme
  • ARBs an angiotensin receptor blocker
  • ARNis Angiotensin receptor-neprilysin inhibitors
  • the method 300 includes generating a medication update and/or a lab order within the EHR based on the initiation and dosing engine (IDE) output.
  • generating a medication and/or lab order within the EHR may include automatically approving the order. In this way, if the patient had been determined to be clinically suitable for up-titration or initiation of one or more therapeutic agent, additional clinician review is not required (unless indicated by the clinician at the time of prescribing the therapeutic regimen evaluation and/or management).
  • the method 300 includes transmitting the generated medication update and/or lab order to the patient’s EHR. Upon transmitting, the method 300 proceeds to 346, at which a notification is sent to the patient (e.g., via patient interface of app 136) for acknowledgement.
  • a notification is sent to the patient (e.g., via patient interface of app 136) for acknowledgement.
  • notification regarding the medication update and/or a lab order generated by the IDE may be directly sent to the patient without waiting for clinician review.
  • the initiation and dosing algorithm may initiate and change medical dosages without the input of a clinician within certain prespecified blood pressure, heart rate, and laboratory parameters, as further discussed below at FIG. 4.
  • the notification to the patient may include links to one or more videos or slideshows to educate patients on the importance of taking the recommended therapeutic regimen at the recommended doses, enabling patients to not only understand the rationale for recommendations, but also advocate for improved treatment for themselves.
  • the patient may have access to the relevant videos and/or slide shows providing education regarding the specific therapeutic agent.
  • the clinician may be notified (e.g., via clinician interface of app 186) regarding the medication update and/or lab order generated by the IDE.
  • the clinician interface may include a decision engine worksheet that indicates the IDE output and the logic behind the DE output. For example, for each recommendation provided by the IDE, the decision conditions visited (also referred to herein as states) and the logic behind the decision condition is displayed to the clinician.
  • An example clinician interface showing the states visited by a decision engine is shown at FIGS. 8A and 8B.
  • the clinician interface may also display, for each run of IDE, one or more therapeutic agent orders generated, and one or more alerts generated (e.g., recheck metabolic lab in 5 days).
  • the method 300 includes monitoring the patient response to IDE prescription, such as side-effects arising from the medication update. Details of monitoring the patient for side-effects will be described below at FIG. 5.
  • FIG. 5 it shows a flow chart illustrating a high-level method 500 for monitoring patient response after a therapeutic regimen is updated.
  • the decision engine such as the initiation and dosing engine or the safety decision engine, for evaluation and/or management of a therapeutic regimen generates a prescription within the EHR, and is acknowledged by the patient
  • the patient response is monitored using one or more remote monitoring devices, such as one or more physiological sensor 106, and/or one or more indication from the patient, for a threshold post-prescription monitoring period (also referred to as patient response monitoring period).
  • the threshold postprescription monitoring period may be based on the type of medication updated and/or medical history of known side-effects and/or medication intolerances of the patient.
  • Method 500 begins at 502.
  • the method 500 includes receiving a response from the patient.
  • remote monitoring data from one or more remote monitoring devices may be used to automatically evaluate a patient’s response to the therapeutic regimen update.
  • remote monitoring data acquired over the post-prescription monitoring period may be used for patient response analysis.
  • a questionnaire may be generated based on the medication update by the IDE or SDE, and transmitted to the patient (e.g., via app 136).
  • the patient may perform a selfevaluation or with help from a care giver, provide responses to the question via the patient interface of the patient-side app.
  • receiving the response from the patient may include one or more of receiving remote monitoring data from one or more remote monitoring devices and receiving response to the questionnaire.
  • method 500 proceeds to 504 and 506.
  • the method 500 includes determining if the patient is able to tolerate the medication update, and at 506, the method 500 includes determining if the patient is experiencing any side-effects.
  • the method 500 may determine that the patient is able to tolerate the medication update and that there are no side-effects if one or more physiological parameters (e.g., heart rate, SBP, oxygen saturation, temperature, respiration rate, degree of stability, etc.) are within respective thresholds and/or threshold ranges over the post-prescription monitoring period and if no side-effects or intolerances are indicated the questionnaire by the patient.
  • physiological parameters e.g., heart rate, SBP, oxygen saturation, temperature, respiration rate, degree of stability, etc.
  • the decision engine may generate a check lab output. Accordingly, if a lab result is indicated in the patient’s health record referenced to the patient, the method 500 may monitor patient data from the EHR as well to evaluate whether the patient is able to tolerate the therapeutic regimen update (e.g., initiation of a medication) based on the lab result.
  • the therapeutic regimen update e.g., initiation of a medication
  • the method 500 ends without making any further changes to the latest therapeutic regimen update. However, if the answer at 504 is NO or if the answer at 506 is YES, the method 500 proceeds to 510.
  • the method 500 includes running the SDE to determine if one or more medications may be discontinued or if the dosage may be decreased to improve tolerance to the medication update and/or reduce side effects.
  • the method 500 further includes generating an SDE output within the EHR. That is, a second update to the therapeutic regimen may be generated.
  • the SDE output generated within the EHR is confirmed by the clinician.
  • the SDE output is sent to the patient for acknowledgement.
  • the SDE output (that is, the second prescription update) made to the therapeutic regimen is automatically sent to the pharmacy.
  • the method 500 returns to 502 for another post-prescription monitoring period.
  • a HF patient is monitored after a therapeutic regimen update, and if needed, additional updates to the therapeutic regimen are provided until the patient is able to tolerate the therapeutic regimen with reduced side-effects.
  • the method 300 proceeds to 306.
  • the method 300 may include evaluating if the clinical stability is above a second lower threshold. If the answer is YES, then the method 300 may proceed to 306; otherwise the method 300 may end and one or more indications regarding a failed attempt to update the therapeutic regimen may be provided to the patient and the clinician.
  • the method 300 includes running the safety decision engine, where a therapeutic agent may be discontinued or decreased.
  • the safety decision engine may monitor for symptoms of drug side effects, acute kidney injury, hyperkalemia, hypotension, and bradycardia. If the data from the remote patient monitoring devices indicates that the patient has met any critical safety thresholds, then the SDE will recommend that the patient either discontinue or decrease the dosage of one or more medication (GDMT or non-GDMT medications). Details of the safety decision engine will be described with respect to FIG. 7.
  • the method 300 includes generating a safety decision engine (SDE) output.
  • the SDE output includes maintaining a current therapeutic regimen or updating the current therapeutic regimen to decrease one or more previously administered therapeutic agent (310) (GDMT or non-GDMT based therapeutic agents) or discontinue one or more previously administered therapeutic agents (312) (GDMT or non-GDMT based therapeutic agents), and/or re-check laboratory test (314) (e.g., basic metabolic profile, eGFR testing, cardiac imaging, etc.).
  • the re-check laboratory test output may be generated responsive to one or more of a potassium level greater than a potassium level threshold, a delta creatinine level greater than a delta creatinine level threshold, initiation of an MRA class of therapeutic agent, initiation of an Angiotensin-converting enzyme (ACE) inhibitor, initiation of an angiotensin receptor blocker (ARBs), and initiation of an Angiotensin receptor-neprilysin inhibitors (ARNis).
  • ACE Angiotensin-converting enzyme
  • ARBs an angiotensin receptor blocker
  • ARNis Angiotensin receptor-neprilysin inhibitors
  • the method 300 Upon generating the SDE output, at 318, the method 300 includes generating the medication update and/or lab order within the EHR. In this case, since SDE was executed, the medication update and/or order within the EHR may be reviewed and approved by the clinician (that is, the medication updates and/or lab orders resulting from SDE alone are reviewed and approved by the clinician). Accordingly, at 320, the method 300 includes transmitting the generated medication update and/or lab order from the SDE to the clinician for approval. Upon receiving clinician approval, the method 300 proceeds to 322.
  • the output of the safety decision engine may be automatically approved and the method may proceed from 318 to 322.
  • other physiological parameters such as respiration rate, oxygen saturation, and/or temperature may be taken into account in determining whether the updated regimen is automatically approved or not.
  • the method 300 includes transmitting a notification to the patient (e.g., via patient interface of app 136) for acknowledgement.
  • the notification may include an indication that only an SDE was executed and that the medication update and/or the lab check order was reviewed and approved by the clinician (or automatically generated responsive to one or more conditions being met as discussed above).
  • the method 300 then proceeds to 348 to monitor patient response to the SDE prescription, details of which are discussed above at FIG. 5.
  • remote monitoring of and remote therapeutic regimen modulation enables clinician outreach to distant areas where repeated visits to a clinic may not be more challenging.
  • therapeutic management through integration of remote monitoring devices, EHR, and/or patient response reduced patient fatigue, which may further improve patient outcome.
  • the therapeutic management methods and systems described herein improves time available for clinician-patient interaction.
  • a clinician prescribes the use of a digital therapeutic decision engine for evaluation and/or management of a therapeutic regimen for a heart failure patient.
  • Prescribing the use of the digital therapeutic decision engine may include setting threshold ranges and/or threshold values for the various physiological parameters (e.g., average heart rate, average SBP, minimum SBP, stability, etc.) and/or various parameters that are obtained by lab and/or imaging tests (e.g., potassium level, delta creatinine level, eGFR level, LVEF percentage, etc.).
  • the threshold range and/or threshold values at the time of the prescription may be automatically set.
  • the decision engine may determine whether a patient is clinically stable enough for a change in his or her medications. If the patient is clinically stable, the decision engine determines if clinician input is required and if not, the decision engine automatically provides recommendation to initiate one medication at a specific dosage or increase dosage of one medication and/or automatically discontinue or decrease dosage of a medication and/or check labs. If the decision engine either initiates or increases the dosage of a medication in the therapeutic regimen, the patient app may (1) educate the patient on the rationale for the decision and (2) ask for the patient’s acknowledgement.
  • a safety decision component of the decision engine may be executed, where the safety decision component provides recommendations to discontinue or decrease the dosage of a specific medication pending patient’s consent either automatically or with clinician input based on pre-specified parameters.
  • a system comprises one or more physiological sensors configured to acquire a set of physiological sensor data from the patient; a processing system comprising at least one processor communicably coupled to at least one non-transitory memory storing a decision engine, the at least one non-transitory memory storing executable instructions that when executed causes the processor to: acquire the set of physiological sensor data from the one or more physiological sensors; acquire a set of patient data from an electronic health record system communicatively coupled to the processor, the electronic health record system storing patient data referenced to the patient, the patient data including one or more therapeutic agents and associated dosages; during a first condition, when a stability of the patient is above a first threshold, process the set of physiological sensor data and the set of patient data according to a first mode of operation of the decision engine and output a first updated therapeutic regimen based on the therapeutic regimen, the therapeutic regimen including the one or more therapeutic agents and associated dosages; and during a second condition, when the stability of the patient is below the first threshold, process the set of physiological sensor data and the set
  • processing according to the first mode of operation of the decision engine includes running the initiation and dosing engine, and processing according to the second mode of operation includes running the safety decision engine.
  • the set of physiological sensor data includes one or more of electrocardiogram (ECG) data, blood pressure data, photopl ethy smogram (PPG) data, gyroscope data, accelerometer data, and body temperature data.
  • ECG electrocardiogram
  • PPG photopl ethy smogram
  • gyroscope data gyroscope data
  • accelerometer data e.gyroscope data
  • body temperature data e.gyroscope data
  • the stability of the patient is determined based on the set of physiological sensor data.
  • the first mode of operation of the decision engine includes updating the therapeutic regimen to provide a change in associated dosage of the one or more therapeutic agents and/or initiate one or more new therapeutic agents, or to provide a discontinuation of the one or more therapeutic agents and/or initiate the one or more new therapeutic agents; and the second mode of operation of the decision engine updates the therapeutic regimen to provide one or more of a decrease in the one or more therapeutic agents or discontinuation of the one or more therapeutic agents without initiating the one or more new therapeutic agents.
  • each of the one or more therapeutic agents and the one or more new therapeutic agents is selected from the group consisting of beta blockers, Angiotensin-converting enzyme (ACE) inhibitors, angiotensin receptor blockers (ARBs), Angiotensin receptor-neprilysin inhibitors (ARNis), Aldosterone receptor antagonists (MRAs), Sodium-glucose transport protein (SGLT2) inhibitors, and other therapeutic agents for treating heart failure.
  • ACE Angiotensin-converting enzyme
  • ARBs angiotensin receptor blockers
  • ARNis Angiotensin receptor-neprilysin inhibitors
  • MRAs Aldosterone receptor antagonists
  • SGLT2 Sodium-glucose transport protein
  • FIG. 4A shows a high-level flow chart illustrating an example method 400 for initiating an initiation and dosing engine in response to a clinician prescribing evaluation and/or maintenance of a therapeutic regimen for a HF patient, according to another embodiment of the disclosure.
  • the method 400 begins at 402. At 402, the method 400 includes receiving one or more physiological sensor data from the patient, and one or more patient data from the patient’s EHR. Step 402 is similar to 302, and will not be repeated for brevity.
  • the method 400 includes receiving, from the EHR, a number of unsuccessful attempts to initiate or up-titrate one or more GDMT medications. For example, if a patient was not clinically stable, an initiation and dosage engine may not be initiated, and accordingly, an unsuccessful attempt may be indicated (e.g., via a counter) and one or more physiological parameters that caused the unsuccessful attempt may be indicated for the patient, and stored in one or more of the cardiac health database and EHR for later retrieval. In some examples, if the initiation and dosing engine is initiated but due to one or more of intolerance to and side-effects resulting from an initiated or up-titrated therapeutic agent, the initiated or up-titrated therapeutic agent may be discontinued or decreased based on patient response.
  • such an event where the patient response to the initiated or up-titrated therapeutic agent resulted in a second update to discontinue or decrease dosage of the therapeutic agent, may be considered as an unsuccessful attempt to initiate or up-titrate one or more GDMT medications. Further, for each unsuccessful attempt to initiate or up-titrate, the corresponding cause and/or status of one or more physiological parameters at the time of unsuccessful event may be indicated.
  • the method 400 includes acquiring, via EHR, one or more known intolerances to GDMT -based therapeutic agents.
  • the method includes determining of the number of unsuccessful attempts is greater than zero. If the answer at 405 is NO, the method 400 proceeds to 406.
  • the method includes prior to running the initiation and dosing engine, automatically setting one or more titration parameters including an average SBP range, an average DBP range, a minimum SBP range, an average heart rate range, and ranges and/or thresholds for lab parameters, including potassium, creatinine, delta creatinine, and eGFR.
  • the automated titration parameters may be based on an initial indication by the clinician at the time of prescription of the automated initiation and dosing engine.
  • the method 400 includes responsive to detection of a previous unsuccessful attempt (that is, when the number of unsuccessful attempts is greater than zero), receiving clinician confirmation and/or specification of one or more titration parameters.
  • the method 400 Upon setting one or more titration parameters, the method 400 proceeds to 410.
  • the method includes determining patient stability based on remote monitoring sensor data. Determination of patient stability is discussed at step 304 at method 300, and therefore, will not be repeated.
  • the method 400 proceed to 412 to evaluate if the patient’s clinical stability is confirmed or if a stability score of the patient is greater than a threshold stability score. If the answer at 412 is YES, the method 400 proceeds to 420 to run the initiation and dosing engine. If the answer at 412 is NO, then the method 400 does not initiate IDE, and subsequently at 416, the method 400 includes indicating an unsuccessful attempt to initiate or up-titrate GDMT medication.
  • the safety decision engine may be initiated.
  • the patient’s stability may be continuously monitored for a threshold duration, and responsive to the patient’s stability decreasing below a second lower threshold, one or more alerts indicating poor stability conditions may be provided to the clinician and/or patient, thereby prompting the clinician and/or patient (or caregiver) to take immediate actions to improve patient stability (e.g., via hospitalization).
  • the method 400 includes determining if a prescription and/or lab order is generated by the initiation and dosing engine within the EHR.
  • the prescription may be to initiate one or more medications, increase dosage of one or more medications, decrease dosage of one or more medication, and/or discontinue one or more medications. If the answer at 424 is NO, the method proceeds to 426 to maintain current therapeutic regimen. The method 400 then ends.
  • the method 400 includes determining if one or more selected physiological parameters are within respective desired ranges.
  • the one or more selected physiological parameters may include one or more of an average SBP, an average DBP, and an average heart rate.
  • the thresholds for this step may be more stringent. For example, the threshold blood pressure range and threshold heart rate range may be more narrow in order to perform automatic approval of the updated therapeutic regimen.
  • the method 400 proceeds to 430 to automatically generate (and approve) a corresponding prescription based on the updated therapeutic regimen (based on output of the IDE) within the EHR based on the output of the initiation and dosage engine. If the answer at 428 is NO, the method 400 proceeds to 432.
  • the method 400 includes transmitting the corresponding prescription to the clinician and receiving clinician approval.
  • the method 400 Upon approval (automatically or via clinician), the method 400 proceeds to 434 to notify the patient.
  • the method 400 includes transmitting the approved prescription to a pharmacy.
  • the method 400 includes determining if the patient has initiated the updated therapeutic regimen. If YES, the method 400 proceeds to 440, to monitor response to the updated treatment regimen, as discussed at FIG. 5. Monitoring response to the updated therapeutic regimen may include (at 442) further updating the therapeutic regimen based on a patient response monitored via one or more remote monitoring devices and/or patient indication of response to a questionnaire, as discussed at FIG. 5. If the answer at 438 is NO, the method 400 may continue monitoring indication of initiation of the updated therapeutic agent from the patient.
  • HF therapy is efficiently customized and/or personalized not only on a patient-to-patient basis, but is also updated in a longitudinal manner (over time) for each patient depending on patient progress.
  • the decision engine also enables clinicians to reduce clinical inertia. Further still, decision making efficiency is improved, which allows the clinician more time for other aspects of therapy.
  • a patient undergoing heart failure therapy with chronic kidney disease, ischemic cardiomyopathy, reduced ejection fraction at 20% is currently prescribed a first therapeutic regimen comprising one or more therapeutic agents.
  • a decision engine may generate a second therapeutic regimen to include a new therapeutic agent. After administration of the new therapeutic regiment and confirmed intake of the new therapeutic agent by the patient, the decision engine may monitor patient response to the new therapeutic agent via one or more remote patient monitoring sensors and patient reported data (input via an app).
  • the decision engine may run the decision engine in the second mode (e.g., safety decision engine) and generate a third therapeutic regimen to either decrease the dosage of the new therapeutic agent or discontinue the new therapeutic agent.
  • the decision engine may continue monitoring the patient response to the third therapeutic regimen to determine if further updates are necessary or maintain the third therapeutic regimen.
  • there may be a period of time (before a next update) when the patient response is monitored but no updates are made.
  • the decision engine monitoring a patient undergoing HF therapy and currently under a first therapeutic regimen may identify a heart condition event (e.g., atrial fibrillation) using data from one or more physiological sensors. Responsive to which, decision engine may generate an updated therapeutic regimen with initiation of a blood thinner. The decision engine, upon receiving confirmation of uptake/administration of the updated therapeutic regimen may perform patient response monitoring as discussed above.
  • a heart condition event e.g., atrial fibrillation
  • the decision engine may manage HF therapy for a 42 year old HF patient who had anterior myocardial infarction.
  • the patient may be initiated on a therapeutic regimen comprising Carvedilol and Entresto and associated doses. Responsive to a lab result indicating intolerance to higher doses of Entresto, the decision engine may generate an updated regimen with lower dosage for Entresto.
  • FIGS. 6A - 6D it shows an example method 600 for updating a therapeutic regimen for a HF patient.
  • method 600 shows operation of an initiation and dosing engine (IDE).
  • IDE initiation and dosing engine
  • a stability check may be performed and therapeutic dosage limits for one or more GDMT-based therapeutic agents may be provided to the IDE (either automatically or based on clinician indication) as discussed at FIGS. 3, 4A and 4B.
  • the IDE may be initiated only when the patient is confirmed to the clinically stable to initiate a therapeutic agent and/or up-titrate a currently prescribed therapeutic agent.
  • the method 600 below will be described with respect to example thresholds and/or ranges for various physiological parameters (estimated and/or measured via one or more physiological sensors) and laboratory parameters (acquired from the patient’s EHR); however, it will be appreciated that the ranges and thresholds may be customized based on a given health condition for the patient.
  • the method 600 begins at 602. At 602, the method 600 includes determining if a combination of GDMT-based therapeutic agents and non-GDMT based therapeutic agents are included in the therapeutic regimen for the HF patient.
  • GDMT-based therapeutic agents are therapeutic agents prescribed to patients with HF according to guideline-directed medical therapy (GDMT).
  • Non-GDMT based therapeutic agents are therapeutic agents that are not indicated in the GDMT.
  • the method 600 proceeds to 604 to stop combination medications and subsequently to 606 to start constituents except sacubitril/valsartan, and then proceeds to 608. If the answer at 602 is NO, the method 600 directly proceeds to 608.
  • the method 600 includes running the safety decision engine (SDE).
  • the SDE may monitor for indications of one or more of acute kidney injury, hyperkalemia, hypotension, and bradycardia. Further, if the remote patient monitoring data indicates that the patient has met any critical safety thresholds, then the SDE may recommend that the patient either discontinue or decrease the dosage of a therapeutic agent or provide an indication to recheck one or more laboratory tests. Accordingly, prior to increasing a dosage of a therapeutic agent and/or initiating a new therapeutic agent, the SDE may be executed. Details of the SDE are described with respect to FIG. 7.
  • the method 600 proceeds to 610.
  • the method 600 includes determining if SDE has indicated decrease or discontinuation of one or more medications. If YES, the method 600 proceeds to 614 to update the therapeutic regimen based on SDE output to decrease a therapeutic agent and/or discontinue a second therapeutic agent. If the SDE output indicated no titration (that is, if answer at 610 is NO), the method 600 proceeds to 612 to maintain current therapeutic regimen after SDE output. The method 600, after updating or maintaining the therapeutic regimen after SDE, proceeds to 616.
  • the method 600 includes determining whether a systolic blood pressure (SBP) is less than or equal to 140 mm Hg. If YES, the method 600 proceeds to 618. At 618, the method 600 includes determining if the patient is on non-GDMT hypertensive medication. If the patient is on non-GDMT hypertensive medication, the answer at 618 is YES, and the method proceeds to 620. At 620, the method 600 includes decreasing the non- GDMT hypertensive medication or discontinuing the non-GDMT hypertensive medication.
  • SBP systolic blood pressure
  • the method 600 proceeds to 622 continued at FIG. 6B.
  • the method 600 includes determining if the patient is on non-dihydropyradine calcium channel blocker. If the answer at 622 is YES, the method 600 proceeds to 624.
  • the method 600 includes adjusting blood pressure medication or beta blocker (BB) medication based on SBP and current BB type and dosage. For example, if the SBP is greater than or equal to 110, a GDMT BB may be initiated or a dosage of a GDMT BB may be increased, or a non-GDMT BB may be converted to equal dosage GDMT BB. Further, if the SBP is greater than or equal to 100 but less than 110, then conversion or dosage increase to metroprolol may be performed up to level 3. If the SBP is less than 100, then non- dihydropridine may be discontinued. The method 600 then returns to 626.
  • BB beta blocker
  • the method 600 includes determining if conditions for MRA initiation and/or SLGT2 adjustment are met.
  • conditions for MRA and/or SLGT2 adjustment may include 1) the patient on GDMT BB and on Angiotensin Receptor- Neprilysin Inhibitor (ARNi) and SBP less than 140 and heart rate (HR) less than 80 OR 2) the patient is ARNi intolerant and on GDMT BB and on (Angiotensin-converting enzyme inhibitor (ACEi) level 3,4, or 5, or on Angiotensin II receptor blocker (ARB) level 2, 3, 4, or 5) and SBP less than 140 and HR less than 80.
  • ACEi Angiotensin-converting enzyme inhibitor
  • ARB Angiotensin II receptor blocker
  • the method 600 proceeds to 628; otherwise, the method 600 proceeds to 636 continued at FIG. 6C.
  • the method 600 includes determining is SBP is greater than 95 and delta creatinine level is less than 0.5. If the answer at 628 is NO, the method proceeds to 636 at FIG. 6C. If the answer at 628 is YES, the method 600 proceeds to 630 determine if Spirinolactone (MRA) and/or Dapagliflosin (SLGT2) is able to be initiated (that is, if no prior intolerances or side-effects to MRA and/or SLGT2 are indicated in the patient’s EHR). If NO, the method 600 proceeds to 636 at FIG. 6C.
  • MRA Spirinolactone
  • SLGT2 Dapagliflosin
  • the method 600 proceeds to 632 to determine of MRA and SLGT2 are currently prescribed. If the answer at 632 is YES, the method 600 proceeds to 636 at FIG. 6C; otherwise if MRA or SLGT2 are not currently prescribed, the method 600 proceeds to 634.
  • the method 600 includes initiating Dapagliflosin (SLGT2) or Spirinolactone (MRA) based on one or more of Potassium, delta Creatinine, ejection fraction, sex, creatinine, and current SLGT2 or MRA prescriptions. [00143] Referring to FIG. 6C, it continues from FIG. 6B.
  • the method 600 includes determining if HR is greater than or equal to 65 and if GDMT BB is able to be increased. If the answer at 636 is YES, the method 600 proceeds to 638 to determine if the patient is currently on a BB medication. If the answer at 638 is NO, the patient is not on a BB, and the method proceeds to 660 to initiate metoprolol or carvedilol or determine notitration based on systolic blood pressure, presence of permanent pacemaker, whether on ACEi/ARB/ARNi, and/or heart rate. If the answer at 638 is YES, the method 600 proceeds to 640 to determine if the patient is on GDMT BB.
  • the method 600 includes converting to GDMT BB or discontinuing non-GDMT BB based on SBP and/or HR.
  • the method 600 proceeds to 670 continued at FIG. 6D.
  • the method 600 includes determining if the patient is on a non-GDMT BB. If the answer at 644 is YES, the method proceeds to 642 to convert to GDMT BB or discontinuing non-GDMT BB based on SBP and/or HR. If the answer at 644 is NO, the method 600 proceeds to 646 to determine is the patient is on ACEi/ARNi/ARB. If the answer at 646 is NO, the method 600 proceeds to 652.
  • the method 600 includes starting sacubitril/valsartan, or starting ACEi at level 2, or starting ACEi at level 3, or starting Lisinopril or performing no titration based on SBP, potassium, delta creatinine, and/or ARNi intolerance. If the answer at 646 is YES, the method proceeds to 648 to first determine if the patient is on GDMT BB, and if so, the method 600 proceeds to 654 to optimize ACEi/ARNi/ARB. If the answer at 648 is NO, the method 600 proceeds to 659 to determine is the patient is on pacemaker. If yes, the method 600 proceeds to 660. If the answer at 659 is NO, the method 600 proceeds to 662.
  • the method 600 includes initiating metoprolol responsive to heart rate greater than 60; otherwise, the method 600 includes determining if SGLT2 and/or MRA are able to be initiated. The method 600 then proceeds to 664. If conditions at 664 are met, the method 600 proceeds to 666 to uptitrate GDMT BB or ARNI based on SBP >100; otherwise performing no titration. If conditions at 664 are not met, the method 600 proceeds to 680 at FIG. 6D.
  • the method 600 includes determining if the patient is on one or more of ACEi, ARB, and ARNI. If the answer at 670 is NO, the method proceeds to 674. At 674, the method 600 includes initiating ARNi based on SBP, K, and dCr, if tolerant; otherwise initiating ACEi. No titration if SBP>95 & K ⁇ 5.0 & dCr 0.5 is not satisfied. If the answer at 670 is YES, the method 600 proceeds to 672 to determine if HR is greater than or equal to 80 and if SBP and/or GDMT BB conditions indicate uptitration.
  • the method 600 proceeds to 676 to uptitrate GDMT BB based on fast heart rate. If the answer at 672 is NO, the method 600 proceeds to 678 to update GDMT BB OR initiate or update ARNi OR update ARNi OR if patient is ARNi intolerant, update ACE or ARB.
  • method 600 proceeds to 680.
  • the method 600 includes if unable to optimize GDMT BB, ARNi, ACEi, or ARB, initiate MRA or SGTL2 if not already on it. The 600 method then ends.
  • FIG. 7 shows a high-level flow chart illustrating an example method 700 for decreasing or discontinuing one or more therapeutic agents in a therapeutic regimen for HF patients.
  • method 700 may be implemented when the decision engine is operated in a safety decision engine (SDE) mode (also referred to as second mode of decision engine), such as when a patient stability is below a threshold, or for monitoring patient response to a change in the therapeutic regimen (e.g., after a therapeutic agent has been increased or initiated or decreased or discontinued from a previous therapeutic regimen update).
  • the method 700 may be implemented for monitoring for symptoms of drug side effects, acute kidney injury, hyperkalemia, hypotension, and/or bradycardia.
  • the method 700 may generate an updated therapeutic regimen, wherein the updates therapeutic regimen includes discontinuation or decrease in the dosage associated with one or more therapeutic agents.
  • the method 700 may recommend the updates, and the recommendations for updating the therapeutic regimen may then be approved by the clinician.
  • the method 700 may automatically generate updates to the therapeutic regimen.
  • Method 700 begins at 702. At 702, the method 700 includes determining if a potassium level is greater than or equal to 5 nmol/L or if delta creatinine value is greater than or equal to 0.5 mg/dL. If YES, the method 700 proceeds to 704 to determine if the patient is on KC1. If YES, the method 700 proceeds to 706 to update a therapeutic regimen to discontinue KC1, and then returns to 760. If the patient is not on KC1, the method 700 proceeds to 760 from 704.
  • the method 700 includes based on delta creatinine levels and/or potassium levels, and whether on MRA, ACEi or ARB or ARNi, updating to adjust treatment regimen to decrease or discontinue MRA dosage (752), or decrease or discontinue ACEi dosage (754), or decrease or discontinue ARB dosage (756), or decrease or discontinue ARNi dosage (758).
  • the MRA dosage is updated to reduce to a lower lever if currently at levels 5, 4, 3, or 2. If the MRA dosage is currently at level 1, then the update includes discontinuation of MRA.
  • the method 700 updates the therapeutic regimen to discontinue MRA.
  • ACEi, ARB, or ARNi may be discontinued or the corresponding dosage is may be decreased.
  • the method 700 provides updates to reduce dosage to a lower level or discontinue a therapeutic agent.
  • kidney function indicated by potassium and delta creatinine levels is taken into account in making updates to the therapeutic regimen for decreasing or discontinuing a therapeutic agent.
  • the method 700 includes determining if an average SBP is less than or equal to 95 and if a minimum SBP is less than 90.
  • the blood pressure values e.g., average SBP, minimum SBP, average DBP
  • the processing system e.g., server 150
  • remotely monitored blood pressure data is used for providing adjustments to a treatment regimen.
  • the method 700 includes providing an update based on heart rate (HR) less than threshold for bradycardia and/or minimum SBP less than 90 mm Hg, and whether on non-GDMT hypertensive medication or BB or ACEi or ARB or ARNi.
  • HR heart rate
  • update is provided to adjust treatment regimen to discontinue non-GDMT hypertensive medication (722), or decrease or discontinue BB (724), or decrease or discontinue ACEi (726), or decrease or discontinue ARB (730), or decrease or discontinue ARNi (732).
  • the respective medication is decreased to a lower level or discontinued based on minimum SBP being less than 90 and/or heart rate less than a threshold (e.g., 60).
  • a threshold e.g. 60
  • the method 700 includes updating the therapeutic regimen based on whether the patient is on a combination of a beta blocker(BB) and ACEi, ARB, or ARNi, and minimum SBP less than 90 and HR less than a second threshold (e.g., 65), which may be greater than the threshold at 720, wherein the update includes a decrease or discontinuation of BB or one of ACEi, ARB, or ARNi. That is, an update is provided to decrease or discontinue BB (742), or decrease or discontinue ACEi (744), or decrease or discontinue ARB (746), or decrease or discontinue ARNi (748), or No titration (750). The method 700 then ends.
  • a second threshold e.g. 65
  • the method 700 checks serum electrolyte (potassium) and metabolite (delta creatinine) levels using patient data from the EHR for indications of hyperkalemia and abnormal kidney function, checks physiological parameters (e.g., minimum SBP, average SBP, an HR) using remote monitoring data for indications of hypotension and bradycardia, and provides updates a therapeutic regimen, for example, to decrease or discontinue one or more therapeutic agents.
  • serum electrolyte potassium
  • metabolite delta creatinine
  • one or more of the updates discussed above may be provided as recommendations to the therapeutic regimen. Further, upon review and approval by a clinician, the therapeutic regimen may be updated with recommendations provided by the safety decision engine.
  • a method comprises generating an updated therapeutic regimen for a heart failure patient based on one or more physiological parameters of the patient acquired via one or more remote monitoring devices and a set of patient data acquired via the patient’s health record; and administering the updated therapeutic regimen to the patient; wherein the updated therapeutic regimen comprises one or more of an increase in dosage of an at least one previously administered therapeutic agent and an initiation of a new therapeutic agent, the new therapeutic agent different than the previously administered therapeutic agent.
  • the updated regimen comprises a decrease or discontinuation in dosage of the previously administered therapeutic agent.
  • a method comprises receiving a set of heart rate data for a patient with a heart failure condition output from a wearable sensor; receiving a patient profile referenced to the patient comprising a therapeutic dosage regimen comprising at least one therapeutic and an associated dosage; processing the set of heart rate data using a model to modify the therapeutic dosage regimen and output an updated therapeutic dosage regime; and administering to the patient the updated therapeutic dosage regime.
  • processing the set of heart rate data using the model to modify the therapeutic dosage regimen further comprises: receiving a set of blood pressure data output from a blood pressure sensor; and processing the set of blood pressure data using the model.
  • the set of heart rate data comprises an average heart rate over 1, 2, 3, 4, 5, or 6 hours.
  • the set of heart rate data comprises an average weekly heart rate.
  • the model comprises comparing the set of heart rate data to a predetermined threshold heart rate.
  • the at least one therapeutic is at least one beta-blocker chosen from atenolol, betaxolol, bisoprolol, carvedilol, esmolol, labetalol, metoprolol, nadolol, pindolol, propranolol, sotalol, timolol, acebutalol, oxprenolol, carvedilol, and penbutolol.
  • beta-blocker chosen from atenolol, betaxolol, bisoprolol, carvedilol, esmolol, labetalol, metoprolol, nadolol, pindolol, propranolol, sotalol, timolol, acebutalol, oxprenolol, carvedilol, and penbutolol.
  • the at least one therapeutic is at least one or more of bisoprolol, carvedilol, metoprolol succinate, captopril, enalapril, fosinopril, Lisinopril, perindopril, quinapril, Ramipril, trandalopril, candesartan, losartan, valsartan, olmesartan, sacubitril / valsartan, spironolactone, or eplerenone.
  • the patient profile comprises at least one first therapeutic previously administered to the patient and wherein the updated therapeutic dosage regime comprises at least a second therapeutic different than the at least one first therapeutic.
  • the set of heart rate data comprises an average weekly heart rate and the predetermined threshold heart rate comprises 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, or 65 bpm.
  • the model comprises a set of therapeutics that are administered sequentially in a predetermined order.
  • the set of heart rate data comprises an average heart rate for at least four hours and the predetermined threshold heart rate comprises less than 50 bpm.
  • the model comprises determining at least one therapeutic based on a class of the at least one therapeutic and a set of classes of therapeutics previously administered to the patient.
  • a method for managing a therapeutic regimen of a patient diagnosed with heart failure comprising: receiving a first set of physiological sensor data acquired from the patient during a first time period, the first set of physiological sensor data output via a one or more remote monitoring devices; receiving a set of patient data from a patient profile referenced to the patient, the set of patient data including the therapeutic regimen comprising at least one therapeutic agent and an associated dosage; processing the first set of physiological sensor data and the set of patient data based on a patient stability to output an updated therapeutic regimen; and administering the updated therapeutic regimen to the patient.
  • processing the first set of physiological sensor data and the set of patient data based on the patient stability comprises determining a stability score for the patient based on the first set of physiological sensor data, and outputting the updated therapeutic regimen responsive to the stability score greater than a threshold score; otherwise, continuing administering the therapeutic regimen to the patient without updates.
  • the updated therapeutic regimen comprises a change in the associated dosage of the at least one therapeutic agent or at least a second therapeutic agent and a second associated dosage for the second therapeutic agent, the second therapeutic agent different than the at least one therapeutic agent.
  • the updated therapeutic regimen comprises discontinuation of the at least one therapeutic agent.
  • processing the first set of physiological sensor data and the set of patient data to output the updated therapeutic regimen further comprises generating one or more alerts, the one or more alerts comprising an indication to perform one or more of a laboratory test and an imaging test.
  • a fifth example of the method which optionally includes one or more of the first through fourth examples, monitoring a patient response to the updated therapeutic regimen through one or more of a set of indications received from the patient and a second set of physiological sensor data acquired from the patient during a second time period, the second set of physiological sensor data output via the one or more remote monitoring devices; and responsive to the patient response indicating one or more of an intolerance to the updated regimen and a sideeffect to the updated regimen, processing the second set of physiological sensor data and the set of patient data to output a second updated therapeutic regimen, and administering the second updated therapeutic regimen to the patient; otherwise, continuing administering the updated therapeutic regimen.
  • the second updated therapeutic regimen comprises a change in the second associated dosage of the second therapeutic agent or discontinuation of the second therapeutic agent.
  • the second set of physiological sensor data and the set of patient data to output the second updated therapeutic regimen is based on one or more of a potassium level, a delta creatinine level, a minimum systolic blood pressure, an average systolic blood pressure, and an average heart rate.
  • processing the first set of physiological sensor data and the set of patient data to output the updated therapeutic regimen is based on a guideline-directed medical therapy (GDMT).
  • the first set of physiological sensor data includes one or more of electrocardiogram (ECG) data for measuring an average heart rate of the patient and blood pressure data for measuring an average systolic blood pressure, an average diastolic blood pressure, and a minimum systolic blood pressure; and wherein the patient data includes one or more of a potassium level, a delta creatinine level, a creatinine level, an eGFR level, a left ventricular ejection fraction, a type of heart failure, a patient height, a patient weight, and a patient sex.
  • ECG electrocardiogram
  • the first set of physiological sensor data further includes one or more of a gyroscope data and an accelerometer data for measuring a degree of sway of the patient.
  • the stability score is based on one or more of the average heart rate, the average systolic blood pressure, and the degree of sway of the patient.
  • at least one of the one or more remote monitoring devices is a wearable device.
  • the at least one therapeutic agent is at least one beta-blocker chosen from atenolol, betaxolol, bisoprolol, carvedilol, esmolol, labetalol, metoprolol, nadolol, pindolol, propranolol, sotalol, timolol, acebutalol, oxprenolol, carvedilol, and penbutolol.
  • beta-blocker chosen from atenolol, betaxolol, bisoprolol, carvedilol, esmolol, labetalol, metoprolol, nadolol, pindolol, propranolol, sotalol, timolol, acebutalol, oxprenolol, carvedilol, and penbutolol.
  • the at least one therapeutic agent is at least one or more of Bisoprolol, Carvedilol, Metoprolol Succinate, Captopril, Enalapril, Fosinopril, Lisinopril, Perindopril, Quinapril, Ramipril, Trandalopril, Candesartan, Losartan, Valsartan, Olmesartan, Sacubitril / Valsartan, Spironolactone, Eplerenone, Dapagliflozin, Empagliflosin, Canagliflozin, and Ertugliflosin.
  • each of the at least one therapeutic agent and the at least second therapeutic agent is selected from the group consisting of beta blockers, Angiotensin-converting enzyme (ACE) inhibitors, angiotensin receptor blockers (ARBs), Angiotensin receptor-neprilysin inhibitors (ARNis), Aldosterone receptor antagonists (MRAs), Sodium-glucose transport protein (SGLT2) inhibitors, and other therapeutic agents for treating heart failure.
  • ACE Angiotensin-converting enzyme
  • ARBs angiotensin receptor blockers
  • ARNis Angiotensin receptor-neprilysin inhibitors
  • MRAs Aldosterone receptor antagonists
  • SGLT2 Sodium-glucose transport protein
  • a method comprises: generating an updated therapeutic regimen for a patient diagnosed with heart failure based on a first set of physiological parameters of the patient acquired via one or more remote monitoring devices and a set of patient data acquired via the patient’s health record; and administering the updated therapeutic regimen to the patient; wherein the updated therapeutic regimen comprises a change in dosage of at least one previously administered therapeutic agent and/or an initiation of at one new therapeutic agent, the new therapeutic agent different from the previously administered therapeutic agent.
  • generating the updated therapeutic regimen is based on a stability of a patient to tolerate up-titration of the at least one previously administered therapeutic agent and/or the initiation of the at least one new therapeutic agent.
  • the stability of the patient is based on one or more of an average heart rate within a threshold heart rate range, an average systolic blood pressure within a threshold systolic blood pressure range, and a degree of sway of the patient within a threshold range.
  • the method further comprises monitoring a patient response to the updated therapeutic regimen through one or more of a set of indications of side-effects received from the patient and a second set of physiological parameters acquired from the patient via the one or more remote monitoring devices after administering the updated therapeutic regimen; and responsive to the patient response indicating one or more of an intolerance to the updated regimen and a side-effect to the updated regimen, generating a second updated therapeutic regimen based on the second set of physiological parameters and the set of patient data, and administering the second updated therapeutic regimen to the patient; otherwise, continuing administering the updated therapeutic regimen.
  • the first set of physiological parameters include one or more of an average heart rate, an average systolic blood pressure, an average diastolic blood pressure, and a minimum systolic blood pressure; and wherein the patient data includes one or more of a potassium level, a delta creatinine level, a creatinine level, an eGFR level, a left ventricular ejection fraction, a type of heart failure, a patient height, a patient weight, and a patient sex.
  • administering the updated regimen to the patient comprises automatically storing the updated therapeutic regimen within the patient’s health record and transmitting a notification to the patient, the notification including the new therapeutic agent in the updated regimen and an instructional indication regarding the new therapeutic agent.
  • the method includes automatically transmitting the updated therapeutic regimen to an associated pharmacy computing system referenced in the patient’s health record.
  • each of the at least one previously administered therapeutic agent and the at least one new therapeutic agent is selected from the group consisting of beta blockers, Angiotensinconverting enzyme (ACE) inhibitors, angiotensin receptor blockers (ARBs), Angiotensin receptor-neprilysin inhibitors (ARNis), Aldosterone receptor antagonists (MRAs), Sodiumglucose transport protein (SGLT2) inhibitors, and other therapeutic agents for treating heart failure.
  • ACE Angiotensinconverting enzyme
  • ARBs angiotensin receptor blockers
  • ARNis Angiotensin receptor-neprilysin inhibitors
  • MRAs Aldosterone receptor antagonists
  • SGLT2 Sodiumglucose transport protein
  • a system for managing a therapeutic regimen for a patient with heart failure comprises one or more physiological sensors configured to acquire a set of physiological sensor data from the patient; a processing system comprising at least one processor communicably coupled to at least one non-transitory memory storing a decision engine, the at least one non-transitory memory storing executable instructions that when executed causes the processor to: acquire the set of physiological sensor data from the one or more physiological sensors; acquire a set of patient data from an electronic health record system communicatively coupled to the processor, the electronic health record system storing patient data referenced to the patient, the patient data including one or more therapeutic agents and associated dosages; during a first condition, when a stability of the patient is above a first threshold, process the set of physiological sensor data and the set of patient data according to a first mode of operation of the decision engine and output a first updated therapeutic regimen based on the therapeutic regimen, the therapeutic regimen including the one or more therapeutic agents and associated dosages; and during a second condition, when the stability of the patient is below the
  • the set of physiological sensor data includes one or more of electrocardiogram (ECG) data, blood pressure data, photoplethysmogram (PPG) data, gyroscope data, accelerometer data, and body temperature data.
  • ECG electrocardiogram
  • PPG photoplethysmogram
  • gyroscope gyroscope
  • accelerometer data
  • body temperature data body temperature data.
  • the first mode of operation of the decision engine includes updating the therapeutic regimen to provide a change in associated dosage of the one or more therapeutic agents and/or initiate one or more new therapeutic agents, or to provide a discontinuation of the one or more therapeutic agents and/or initiate the one or more new therapeutic agents; and wherein the second mode of operation of the decision engine updates the therapeutic regimen to provide one or more of a decrease in the one or more therapeutic agents or discontinuation of the one or more therapeutic agents without initiating the one or more new therapeutic agents.
  • each of the one or more therapeutic agents and the one or more new therapeutic agents is selected from the group consisting of beta blockers, Angiotensin-converting enzyme (ACE) inhibitors, angiotensin receptor blockers (ARBs), Angiotensin receptor-neprilysin inhibitors (ARNis), Aldosterone receptor antagonists (MRAs), Sodium-glucose transport protein (SGLT2) inhibitors, and other therapeutic agents for treating heart failure.
  • ACE Angiotensin-converting enzyme
  • ARBs angiotensin receptor blockers
  • ARNis Angiotensin receptor-neprilysin inhibitors
  • MRAs Aldosterone receptor antagonists
  • SGLT2 Sodium-glucose transport protein
  • a method for treating a patient diagnosed with heart failure comprises: modulating, via a processor, a current therapeutic regimen for the patient based on one or more outputs from one or more remote patient monitoring devices and/or one or more patient data from a patient electronic profile referenced to the patient; wherein the current therapeutic regimen comprises one or more therapeutic agents and associated dosages; and wherein the one or more patient monitoring devices includes one or more blood pressure sensors, one or more ECG sensors, one or more gyroscopes, and/or one or more accelerometers.
  • the method further comprises administering the modulated therapeutic regiment to the patient.
  • the method further comprises monitoring response to the modulated therapeutic regimen based on the one or more remote monitoring devices and/or the one or more patient data and/or input from the patient via a patient portal communicatively coupled to the processor.
  • modulating the current therapeutic regimen includes increasing or decreasing or discontinuing associated dosages of the one or more therapeutic agents.
  • modulating the current therapeutic regimen includes initiating one or more new therapeutic agents, the one or more new therapeutic agents different from the one or more therapeutic agents.
  • a fifth example which optionally includes one or more of the first through fourth examples, responsive to determining the patient stability is not below a threshold stability level, modulating the current therapeutic regimen to decrease or discontinue dosage of the one or more therapeutic agents; otherwise modulating the current therapeutic regimen to increase dosage of the one or more therapeutic agents and/or initiate the one or more new therapeutic agents.
  • the one or more therapeutic agents are selected from the group consisting of beta blockers, Angiotensin-converting enzyme (ACE) inhibitors, angiotensin receptor blockers (ARBs), Angiotensin receptor-neprilysin inhibitors (ARNis), Aldosterone receptor antagonists (MRAs), Sodium-glucose transport protein (SGLT2) inhibitors, and other therapeutic agents for treating heart failure.
  • ACE Angiotensin-converting enzyme
  • ARBs angiotensin receptor blockers
  • ARNis Angiotensin receptor-neprilysin inhibitors
  • MRAs Aldosterone receptor antagonists
  • SGLT2 Sodium-glucose transport protein
  • the one or more new therapeutic agents are selected from the group consisting of beta blockers, Angiotensin-converting enzyme (ACE) inhibitors, angiotensin receptor blockers (ARBs), Angiotensin receptor- neprilysin inhibitors (ARNis), Aldosterone receptor antagonists (MRAs), Sodium-glucose transport protein (SGLT2) inhibitors, and other therapeutic agents for treating heart failure.
  • ACE Angiotensin-converting enzyme
  • ARBs angiotensin receptor blockers
  • ARNis Angiotensin receptor- neprilysin inhibitors
  • MRAs Aldosterone receptor antagonists
  • SGLT2 Sodium-glucose transport protein
  • the one or more remote patient monitoring devices are wearable devices.
  • FIGS. 8 A and 8B illustrates examples of an application user interface, that includes various patient information, patient history, and therapeutic history. Accordingly, the system may then output through the interface (e.g. a display, which is shown in dashed line), a new treatment regimen. As shown, the clinician interface includes options for the clinician to set various thresholds, including limits for the various medications. Further, the clinician interface outputs one or more alerts, including the decision states that were involved in modulating or updating a given therapeutic regimen.
  • the interface e.g. a display, which is shown in dashed line
  • the clinician interface includes options for the clinician to set various thresholds, including limits for the various medications. Further, the clinician interface outputs one or more alerts, including the decision states that were involved in modulating or updating a given therapeutic regimen.
  • FIGS. 9A and 9B illustrate tables showing various classes of drugs used to treat heart failure patients and various dosage levels.
  • various decision engines are disclosed that may titrate the dosages of the therapeutics to different levels listed in the table based on sensor data received by the system and other data as disclosed herein.
  • FIGS. 10A and 10B are block diagrams illustrating a first therapeutic regimen update and a second therapeutic regimen update for a first heart failure patient.
  • FIGS. 10A and 10B show example decision engine inputs, decision engine evaluation states including logic that drive the output recommendations, and decision engine output recommendations for the first patient.
  • FIGS. 11 A, 11B, and 11C are block diagrams illustrating a first therapeutic regimen update, a second therapeutic regimen update, and a third therapeutic regimen update for a second heart failure patient.
  • FIGS. 11 A, 11B, and 11C show example decision engine inputs, decision engine evaluation states including logic that drive the output recommendations, and decision engine output recommendations for the second patient.
  • the disclosure herein may be implemented with any type of hardware and/or software, and may be a pre-programmed general purpose computing device.
  • the system may be implemented using a server, a personal computer, a portable computer, a thin client, or any suitable device or devices.
  • the disclosure and/or components thereof may be a single device at a single location, or multiple devices at a single, or multiple, locations that are connected together using any appropriate communication protocols over any communication medium such as electric cable, fiber optic cable, or in a wireless manner.
  • modules which perform particular functions. It should be understood that these modules are merely schematically illustrated based on their function for clarity purposes only, and do not necessary represent specific hardware or software. In this regard, these modules may be hardware and/or software implemented to substantially perform the particular functions discussed. Moreover, the modules may be combined together within the disclosure, or divided into additional modules based on the particular function desired. Thus, the disclosure should not be construed to limit the present invention, but merely be understood to illustrate one example implementation thereof.
  • the computing system can include clients and servers.
  • a client and server are generally remote from each other and typically interact through a communication network. The relationship of client and server arises by virtue of computer programs running on the respective computers and having a client-server relationship to each other.
  • a server transmits data (e.g., an HTML page) to a client device (e.g., for purposes of displaying data to and receiving user input from a user interacting with the client device).
  • client device e.g., for purposes of displaying data to and receiving user input from a user interacting with the client device.
  • Data generated at the client device e.g., a result of the user interaction
  • Implementations of the subject matter described in this specification can be implemented in a computing system that includes a back-end component, e.g., as a data server, or that includes a middleware component, e.g., an application server, or that includes a front-end component, e.g., a client computer having a graphical user interface or a Web browser through which a user can interact with an implementation of the subject matter described in this specification, or any combination of one or more such back-end, middleware, or front-end components.
  • the components of the system can be interconnected by any form or medium of digital data communication, e.g., a communication network.
  • Examples of communication networks include a local area network (“LAN”) and a wide area network (“WAN”), an inter-network (e.g., the Internet), and peer-to-peer networks (e.g., ad hoc peer-to-peer networks).
  • LAN local area network
  • WAN wide area network
  • inter-network e.g., the Internet
  • peer-to-peer networks e.g., ad hoc peer-to-peer networks.
  • Implementations of the subject matter and the operations described in this specification can be implemented in digital electronic circuitry, or in computer software, firmware, or hardware, including the structures disclosed in this specification and their structural equivalents, or in combinations of one or more of them.
  • Implementations of the subject matter described in this specification can be implemented as one or more computer programs, i.e., one or more modules of computer program instructions, encoded on computer storage medium for execution by, or to control the operation of, data processing apparatus.
  • the program instructions can be encoded on an artificially-generated propagated signal, e.g., a machine-generated electrical, optical, or electromagnetic signal that is generated to encode information for transmission to suitable receiver apparatus for execution by a data processing apparatus.
  • a computer storage medium can be, or be included in, a computer-readable storage device, a computer-readable storage substrate, a random or serial access memory array or device, or a combination of one or more of them.
  • a computer storage medium is not a propagated signal, a computer storage medium can be a source or destination of computer program instructions encoded in an artificially-generated propagated signal.
  • the computer storage medium can also be, or be included in, one or more separate physical components or media (e.g., multiple CDs, disks, or other storage devices).
  • the operations described in this specification can be implemented as operations performed by a “data processing apparatus” on data stored on one or more computer-readable storage devices or received from other sources.
  • data processing apparatus encompasses all kinds of apparatus, devices, and machines for processing data, including by way of example a programmable processor, a computer, a system on a chip, or multiple ones, or combinations, of the foregoing
  • the apparatus can include special purpose logic circuitry, e.g., an FPGA (field programmable gate array) or an ASIC (application-specific integrated circuit).
  • the apparatus can also include, in addition to hardware, code that creates an execution environment for the computer program in question, e.g., code that constitutes processor firmware, a protocol stack, a database management system, an operating system, a cross-platform runtime environment, a virtual machine, or a combination of one or more of them.
  • code that creates an execution environment for the computer program in question e.g., code that constitutes processor firmware, a protocol stack, a database management system, an operating system, a cross-platform runtime environment, a virtual machine, or a combination of one or more of them.
  • the apparatus and execution environment can realize various different computing model infrastructures, such as web services, distributed computing and grid computing infrastructures.
  • a computer program (also known as a program, software, software application, script, or code) can be written in any form of programming language, including compiled or interpreted languages, declarative or procedural languages, and it can be deployed in any form, including as a stand-alone program or as a module, component, subroutine, object, or other unit suitable for use in a computing environment.
  • a computer program may, but need not, correspond to a file in a file system.
  • a program can be stored in a portion of a file that holds other programs or data (e.g., one or more scripts stored in a markup language document), in a single file dedicated to the program in question, or in multiple coordinated files (e.g., files that store one or more modules, sub-programs, or portions of code).
  • a computer program can be deployed to be executed on one computer or on multiple computers that are located at one site or distributed across multiple sites and interconnected by a communication network.
  • processors suitable for the execution of a computer program include, by way of example, both general and special purpose microprocessors, and any one or more processors of any kind of digital computer.
  • a processor will receive instructions and data from a read-only memory or a random access memory or both.
  • the essential elements of a computer are a processor for performing actions in accordance with instructions and one or more memory devices for storing instructions and data.
  • a computer will also include, or be operatively coupled to receive data from or transfer data to, or both, one or more mass storage devices for storing data, e.g., magnetic, magneto-optical disks, or optical disks.
  • mass storage devices for storing data, e.g., magnetic, magneto-optical disks, or optical disks.
  • a computer need not have such devices.
  • a computer can be embedded in another device, e.g., a mobile telephone, a personal digital assistant (PDA), a mobile audio or video player, a game console, a Global Positioning System (GPS) receiver, or a portable storage device (e.g., a universal serial bus (USB) flash drive), to name just a few.
  • Devices suitable for storing computer program instructions and data include all forms of non-volatile memory, media and memory devices, including by way of example semiconductor memory devices, e.g., EPROM, EEPROM, and flash memory devices; magnetic disks, e.g., internal hard disks or removable disks; magneto-optical disks; and CD-ROM and DVD-ROM disks.
  • the processor and the memory can be supplemented by, or incorporated in, special purpose logic circuitry.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Medical Informatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Physics & Mathematics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Pathology (AREA)
  • Chemical & Material Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Surgery (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring And Recording Apparatus For Diagnosis (AREA)

Abstract

Des systèmes et des méthodes de prise en charge et d'administration de régimes thérapeutiques pour des patients souffrant d'insuffisance cardiaque sont divulgués. Dans certains exemples, cela comprend la surveillance de la fréquence cardiaque d'un patient et d'un électrocardiogramme à l'aide d'un capteur de fréquence cardiaque portable pour fournir une entrée dans un modèle d'arbre de décision pour fournir un régime thérapeutique efficace. De plus, des mesures régulières de pression artérielle peuvent être entrées dans le modèle. Le système peut en outre itérer à travers divers agents thérapeutiques d'insuffisance cardiaque sur la base d'une réponse du patient à des agents thérapeutiques administrés antérieurement.
EP21865231.1A 2020-09-04 2021-09-03 Compositions et méthodes de prise en charge thérapeutique de patients souffrant d'insuffisance cardiaque Pending EP4208080A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063074805P 2020-09-04 2020-09-04
PCT/US2021/049160 WO2022051678A1 (fr) 2020-09-04 2021-09-03 Compositions et méthodes de prise en charge thérapeutique de patients souffrant d'insuffisance cardiaque

Publications (1)

Publication Number Publication Date
EP4208080A1 true EP4208080A1 (fr) 2023-07-12

Family

ID=80492070

Family Applications (1)

Application Number Title Priority Date Filing Date
EP21865231.1A Pending EP4208080A1 (fr) 2020-09-04 2021-09-03 Compositions et méthodes de prise en charge thérapeutique de patients souffrant d'insuffisance cardiaque

Country Status (4)

Country Link
EP (1) EP4208080A1 (fr)
CN (1) CN116209385A (fr)
CA (1) CA3191506A1 (fr)
WO (1) WO2022051678A1 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023164498A1 (fr) * 2022-02-25 2023-08-31 Cedars-Sinai Medical Center Compositions et méthodes de prise en charge thérapeutique de patients souffrant d'insuffisance cardiaque

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8894974B2 (en) * 2006-05-11 2014-11-25 Spectrum Dynamics Llc Radiopharmaceuticals for diagnosis and therapy
US20170231560A1 (en) * 2008-04-24 2017-08-17 Searete Llc Systems and apparatus for measuring a bioactive agent effect
US10980476B2 (en) * 2014-05-26 2021-04-20 Resmed Sensor Technologies Limited Methods and apparatus for monitoring chronic disease

Also Published As

Publication number Publication date
WO2022051678A1 (fr) 2022-03-10
CN116209385A (zh) 2023-06-02
CA3191506A1 (fr) 2022-03-10

Similar Documents

Publication Publication Date Title
US10998101B1 (en) Health management
Sana et al. Wearable devices for ambulatory cardiac monitoring: JACC state-of-the-art review
US20210169409A1 (en) Systems of centralized data exchange for monitoring and control of blood glucose
Prieto-Avalos et al. Wearable devices for physical monitoring of heart: a review
Ip Wearable devices for cardiac rhythm diagnosis and management
Wieringa et al. Wearable sensors: can they benefit patients with chronic kidney disease?
US20130310658A1 (en) Activity Measurement Systems
Penders et al. Wearable sensors for healthier pregnancies
US10553320B1 (en) Personal analysis and chronotherapy
US20240148339A1 (en) Method for providing alert of potential thyroid abnormality
Padwal et al. Comparison of an in-pharmacy automated blood pressure kiosk to daytime ambulatory blood pressure in hypertensive subjects
Wan et al. HRS white paper on clinical utilization of digital health technology
Bassett et al. Wearable Activity Trackers in Clinical Research and Practice.
EP4208080A1 (fr) Compositions et méthodes de prise en charge thérapeutique de patients souffrant d'insuffisance cardiaque
Spatz et al. Wearable digital health technologies for monitoring in cardiovascular medicine
US20230197232A1 (en) Compositions and methods for therapeutic management of heart failure patients
Tate et al. Activity trackers, wearables, noninvasive technologies for early detection, and management of cardiometabolic risks
Hilbel et al. Review of current ECG consumer electronics (pros and cons)
US20220351852A1 (en) System, apparatus, and methods for health monitoring
WO2023164498A1 (fr) Compositions et méthodes de prise en charge thérapeutique de patients souffrant d'insuffisance cardiaque
US20190216336A1 (en) Blood-pressure management
US20230293019A1 (en) Automatically generating protocols or reports based on sensor data from a mobile device
Arulrhaj et al. Digital Interventions in Cardio-diabetes
Petrova et al. The role of pharmaceutical care in self-control intensifying in patients with diabetes mellitus and arterial hypertension
WO2023180443A1 (fr) Système de gestion de l'hydratation

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20230317

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)